Inflammation is Associated With Subclinical Atherosclerosis by Mehta, Vinay Gautam
  
INFLAMMATION IS ASSOCIATED WITH SUBCLINICAL ATHEROSCLEROSIS 
University of Pittsburgh 
 
2006 
Submitted to the Graduate Faculty of 
Graduate School of Public Health in partial fulfillment  
of the requirements for the degree of 
Doctor of Philosophy 
by 
Vinay Mehta 
BA, Washington and Jefferson College, 2000 
MS, SUNY at Albany, 2002 
 
UNIVERSITY OF PITTSBURGH 
GRADUATE SCHOOL OF PUBLIC HEALTH 
by 
 
 
                                                     Vinay Mehta 
It was defended on 
April 3, 2006 
and approved by 
Sheryl Kelsey, PhD, Professor, Department of Epidemiology, Graduate School of Public 
Health, University of Pittsburgh 
 
Anne B. Newman, MD, MPH, Associate Professor, Department of Epidemiology, Graduate 
School of Public Health, University of Pittsburgh 
 
Jen Brach, PhD,PT, Assistant Professor, Department of Physical Therapy, School of Health 
and Rehabilitation Sciences, University of Pittsburgh 
 
Howard Rockette, PhD, Professor and Chair, Department of Biostatistics, Graduate School of 
Public Health, University of Pittsburgh 
 
 Dissertation Advisor: Kim Sutton-Tyrrell, DrPH, MPH, Professor and Vice Chair for 
Academics, Department of Epidemiology, Graduate School of Public Health, University of 
Pittsburgh
This dissertation was presented 
 
 ii 
Copyright © by Vinay Mehta 
2006 
 iii 
 INFLAMMATION IS ASSOCIATED WITH SUBCLINICAL ATHEROSCLEROSIS 
Vinay Mehta, PhD 
University of Pittsburgh, 2006 
Cardiovascular disease increases with age and menopause.  Atherosclerosis directly contributes 
to cardiovascular disease and subclinical markers of atherosclerosis are noninvasive methods that 
help to detect early vascular changes.  Thus, risk factors associated with markers of subclinical 
atherosclerosis may be targeted for interventions in individuals at high risk of developing 
cardiovascular disease.  C-Reactive Protein (CRP), a marker of inflammation, has been found to 
be associated with cardiovascular events in a large number of populations.  However, studies 
examining the association between CRP and markers of subclinical atherosclerosis have been 
limited. 
The cross-sectional association between CRP and central arterial stiffness, assessed by 
carotid-femoral pulse wave velocity (PWV), was tested in a biracial (Caucasian and Black) 
cohort of 154 women transitioning through menopause within the Study of Women’s Health 
Across the Nation (mean age 50.8 ± 2.6; 44.2% Black).  After adjustment for age, systolic blood 
pressure, ethnicity, study site, waist circumference, diastolic blood pressure, and physical 
activity, the mean pulse wave velocity increased with increasing CRP tertiles (758.5 cm/s, 784.5 
cm/s, 861.7 cm/s; p for trend = .01).  Furthermore, the association was stronger in women later in 
their transition compared to women earlier in their transition (p for interaction = .02). 
The cross-sectional association between CRP and systemic arterial stiffness, assessed by 
brachial artery distensibility, was tested in 1069 women of the same cohort (mean age 53.6 ± 2.6 
years).  After adjustment for confounders, the mean distensibility decreased with increasing 
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tertiles of CRP (p for trend = .001).  This pattern was similar in women of different ethnic groups 
and stages of the menopausal transition.   
The association between CRP and three year incident peripheral arterial disease (PAD), 
assessed by the ankle-brachial index (ABI), was tested in a biracial (Caucasian and Black) cohort 
of 1918 older adults within the Health, Aging, Body, and Composition Study (mean age 
73.6±2.9; 40.3% Black).  Participants in the top tertile of CRP had an increased odds of 
developing PAD compared to those in the bottom tertile (OR=1.87, 95% CI= 1.22 to 2.88). 
Given the high prevalence of cardiovascular disease, finding risk factors associated with 
early vascular changes in high risk populations is of public health importance.   
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1.0  GENERAL INTRODUCTION 
1.1 EPIDEMIOLOGY OF CARDIOVASCULAR DISEASE 
Cardiovascular disease is the leading cause of death in the United States for both men and 
women among all ethnic groups1.  Nearly 2500 Americans die of cardiovascular disease each 
day, which equates to one death every thirty seconds.  The magnitude of the problem is so great 
that it claims more lives each year than the next four leading causes of death combined.  
According to the Centers for Disease Control (CDC), if all forms of cardiovascular disease were 
eliminated, life expectancy in the United States would increase by approximately seven years1.  
There is evidence of an increase in risk of cardiovascular disease with age and the menopause.  
In 2002, 68% of the deaths attributed to cardiovascular disease occurred in individuals over the 
age of 751.  Although the number one cause of death for both men and women, cardiovascular 
events increase in women after the menopause2.  Along with the public health implications of the 
disease, there are economic consequences as well.  The estimated direct and indirect cost of 
cardiovascular disease for 2006 is approximately $400 billion1.         
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1.2 ATHEROSCLEROSIS 
Most forms of cardiovascular disease are caused by atherosclerosis3, which involves the 
accumulation of deposits of fatty substances, cholesterol, body cellular waste products, calcium, 
and fibrin within the interior lining of the artery.  This buildup (commonly referred to as a 
plaque) can partially or totally block the flow of blood through the artery and consequently lead 
to cardiovascular outcomes including heart attack or stroke. 
The lesions of atherosclerosis occur in arteries of different size and composition and can 
result in ischemia of the heart, brain, or extremities, leading to infarction4.  The process of 
atherosclerosis may occur early in a person’s life and manifest itself later on5.   
Atherosclerosis has recently been considered an inflammatory disease3,4.  Each 
characteristic lesion of the atherosclerotic process represents a different stage in a chronic 
inflammatory process of the artery.  If the process is uncontrolled, it will continually progress 
into more advanced stages of atherosclerosis.  The initial step in the atherosclerotic process is 
damage to the endothelium4, the lining of the innermost layer of the arterial wall that acts as an 
interface between the blood and the artery.  This initial damage to the endothelium activates cell 
adhesion molecules, which allow the attachment of leukocytes to the endothelial wall3.  Next, 
monocyte chemoattractant protein-1 (MCP-1) triggers the leukocytes to enter the intima (the 
innermost layer of the arterial wall) where they begin to accumulate lipids.  After recruitment to 
the intima, the leukocytes transform into a lipid laden macrophage called a foam cell6.  This is 
considered the first major lesion of the atherosclerotic process--the characteristic “fatty streak”.  
The fatty streak will eventually evolve into a more complex atheroma through multiplication of 
smooth muscle cells that accumulate in the plaque3.  The growing lesion starts to form a fibrous 
cap that causes the arterial lumen, the open space through which blood flows, to narrow and 
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restrict blood flow4.  Rupture of the fibrous cap, caused by a constant influx of macrophages and 
inflammatory cells into the plaque, can lead to thrombosis and occlusion of the arteries resulting 
in clinical events such as heart attack and stroke.   
Several factors contribute to damage of the endothelium including homocysteine 
overload, oxidation of low-density lipoprotein (LDL) cholesterol, and inflammation.  
Homocysteine augments toxicity to the endothelium7, is prothrombotic8, increases the synthesis 
of collagen9, and decreases the bioavailability of the smooth muscle relaxant nitric oxide10.  
Additionally, it is thought to contribute to the oxidation of LDL cholesterol11.  All of these 
effects are related to the progression of atherosclerosis.  Oxidized LDL can contribute to the 
development of atherosclerosis through a number of mechanisms12.  First, it can have direct 
cytotoxic effects on endothelial cells.  Second, it can increase stimuli involved in the migration 
of leukocytes into the intima.  Finally, it may cause proliferation and migration of cells that lead 
to a thickening of the intima and eventual occlusion of the vessel.  The effects of inflammation 
on the development of atherosclerosis will be covered in the section discussing inflammation.   
1.3 SUBCLINICAL ATHEROSCLEROSIS 
The following section introduces the methods used in this dissertation to assess subclinical 
atherosclerosis.  These methods are clinically useful because they provide noninvasive measures 
to detect early vascular change that may predispose certain individuals to cardiovascular disease. 
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1.3.1 Arterial Stiffness 
The artery acts as a buffer by converting pulsatile blood flow from the heart into continuous flow 
to the cells of the body13.  In an elastic artery, a portion of each cardiac stroke volume is retained 
in the proximal arteries during systole.  During diastole, the elastic recoil of the arterial wall 
pushes this “remnant” to the periphery maintaining a critical buffering action.  In a stiff artery, 
the absence of the elastic recoil causes the full stroke volume to be delivered during systole 
leading to increased pulse pressure and workload for the heart. 
Arterial stiffness, an indicator of vascular age, is an important determinant of systolic 
blood pressure and pulse pressure and precedes isolated systolic hypertension14.  It is thought to 
contribute to the age associated increase in cardiovascular disease and is considered a root cause 
of left ventricular hypertrophy, aneurysm formation and rupture, atherosclerosis, stroke, 
myocardial infarction, and renal failure14.    
1.3.2 Pulse Wave Velocity 
Carotid-femoral pulse wave velocity is a simple, noninvasive, and reproducible measure of 
central arterial stiffness15.  A pulse wave is generated with each contraction of the heart and the 
speed in which it travels throughout the arterial tree is dependent on functional and structural 
properties of the arterial wall16.  This pulse wave is composed of an incident wave, which travels 
away from the heart, and a reflective wave, which travels towards the heart.  In elastic arteries, 
the speed of the wave (the pulse wave velocity) is slow and the reflection occurs in diastole 
resulting in increased diastolic blood pressure and coronary perfusion.  In stiff arteries, the speed 
of the wave is fast and the reflected wave merges with the systolic portion of the incident wave 
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leading to increased systolic blood pressure and pulse pressure14.  Thus, stiffer arteries are 
characterized by a higher pulse wave velocity than elastic arteries.   
Prospective studies have shown an association between central arterial stiffness and 
increased cardiovascular and total mortality in clinical and healthy populations17-21.  One study 
found central aortic stiffening to be a strong predictor of cardiovascular and overall mortality 
among patients with end stage renal disease undergoing hemodialysis18.  Another study found 
aortic stiffness to be predictive of cardiovascular and overall mortality among hypertensive 
patients20.  Shoji et al. showed that increased aortic stiffening of patients with end stage renal 
disease and diabetes contributes to an increase in cardiovascular and all-cause mortality19.  A 
study of healthy older adults found elevated levels of aortic stiffness to be associated with 
increased cardiovascular mortality21. 
1.3.3 Brachial Artery Distensibility (Distensibility) 
Distensibility, defined as the percent or relative change in arterial diameter or area for a given 
change in pressure, is inversely related to pulse wave velocity and is a useful measure for 
comparing the stiffness in arteries of different size13.  The clinical advantage of distensibility 
over other methods that measure arterial stiffness is that it is less expensive and easier to 
perform22.  While carotid-femoral pulse wave velocity provides an indicator of central artery 
stiffness, distensibility provides a measure of systemic or overall stiffness. 
A few studies have found an association between brachial artery distensibility and 
cardiovascular risk factors.  Researchers from the Bogulasa Heart Study found a strong negative 
association between blood pressure and distensibility and weaker associations between age and 
distensibility among healthy young adults23.  Additionally, this study found that a clustering of 
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cardiovascular risk factors was more strongly associated with a reduction in distensibility than a 
single risk factor alone24.  Budoff et al. found an association between decreased brachial 
distensibility and higher levels of coronary calcification—indicating the role of distensibility in 
identifying patients with atherosclerotic burden25. 
1.3.4 Peripheral Arterial Disease 
In the United States, peripheral arterial disease (PAD) affects about eight million people and is 
associated with an increased cardiovascular morbidity and mortality26,27.  The prevalence of the 
disease is higher in blacks and older adults28 and its strongest risk factors appear to be cigarette 
smoking and diabetes29.   PAD is considered the “silent killer” because only ten percent of 
persons with the disease have classic symptoms of intermittent claudication1.  Thus, noninvasive 
methods are needed to assess PAD in asymptomatic individuals. 
1.3.5 Ankle-Brachial Index 
The ankle-brachial index (ABI), the ratio of the ankle to arm systolic blood pressure, is a 
noninvasive measure of assessing subclinical PAD.  It is considered the most efficient and 
practical technique for determining the presence and severity of PAD.  A major advantage of the 
ABI is that it can be used to assess prognosis in symptomatic as well as asymptomatic 
individuals.  An ABI of less than 0.9 is indicative of PAD and an ABI of greater than 1.0 is 
generally considered normal30. 
Several studies have found an association between ABI and cardiovascular disease and 
mortality.  Researchers from the Cardiovascular Health Study found participants with an ABI 
less than 0.8 to be more than twice as likely as those with an ABI between 1.0 and 1.5 to have a 
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history of myocardial infarction, angina, congestive heart failure, stroke, or transient ischemic 
attack30.  Another study in this population found an ABI less than 0.9 to be associated with 
increased incidence and recurrence of cardiovascular disease and increased mortality31.  The 
Study of Osteoporotic Fractures, a prospective study examining mortality in white women over 
the age of 65, found an increased four year mortality in women with an ABI less than 0.9 
compared to women with an ABI greater than 0.9 (RR=3.1, 95% CI = 1.7 TO 5.5)32.  A 
prospective study examining participants with systolic hypertension found an ABI less than 0.9 
compared to an ABI greater than 0.9 to be predictive of total mortality (RR=3.8, 95% CI = 2.1 to 
6.9) and cardiovascular mortality (RR=3.7, 95% CI = 1.8 to 7.7)33.  The Edinburgh artery study, 
a population based study of men and women aged 55-74 years, found an ABI less than 0.9 
compared to an ABI greater than 0.9 to be associated with an increased five year total (RR=1.58, 
95% CI = 1.14 to 2.18) and cardiovascular mortality (RR=1.85, 95% CI = 1.15 to 2.97)34. 
1.4 INFLAMMATION 
Inflammation is a feature in the onset, development, and evolution of atherosclerotic lesions3,4.  
Cardiovascular risk factors including hypertension, exposure to tobacco, lipoproteins, and 
elevated glucose promote the release of inflammatory cells into the growing lesion3.  These 
processes result in plaque instability and rupture which leads to clinical cardiovascular outcomes. 
1.4.1 C-Reactive Protein 
C-Reactive Protein (CRP), the most widely directly measured acute phase protein, is 
hardly detectable in plasma but can increase up to a 1000-fold during an acute response.  As a 
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member of the pentraxin family, this protein received its name because it binds to the C- 
polysaccharide of Streptococcus pneumoniae35.  The ability to activate complement36-38 and 
stimulate tissue-factor39,40 production suggests that CRP may have pro-inflammatory effects. 
CRP has a clinical advantage over other inflammatory markers because its assay is well-
validated, inexpensive, and widely available41.  Additionally, it shows little circadian or seasonal 
variability42.  Because of these advantages, the CDC has implemented recommendations for the 
use of CRP as a clinical marker of cardiovascular risk43. 
CRP may initiate and promote atherosclerosis via a number of mechanisms.  Growing 
evidence suggests that CRP acts on monocytes and macrophages, endothelial cells, and smooth 
muscle cells, all of which are associated with the progression of atherosclerosis44.  CRP has been 
found to be associated with reduced production of the smooth muscle relaxant nitric oxide45  and 
also act as a mediator for the chemotactic movement of leukocytes46.  The rupture of the 
atherosclerotic plaque may also be accelerated by CRP47.  Finally, studies have implicated CRP 
as an activator of complement36-38 and stimulator of tissue factor production39,40.       
Several prospective studies in healthy and clinical populations have found a relationship 
between CRP and increased incidence of cardiovascular events48-59.  The Women’s Health Study 
found increased CRP to predict first cardiovascular event, including nonfatal myocardial 
infarction, nonfatal ischemic stroke, coronary revascularization, and death from cardiovascular 
causes52.  The Physicians Health Study, an investigation of apparent healthy men, found 
significantly elevated levels of CRP among individuals who developed vascular events compared 
to individuals who remained free of vascular events48-51.  The Monitoring Trends and 
Determinants in Cardiovascular Disease (MONICA) Study examined the relationship between 
CRP and clinical cardiovascular outcomes among men who were free of clinical coronary artery 
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disease58.  This group found an increased risk of future coronary events with increasing levels of 
CRP.  Among individuals with established vascular disease, the European Concerted Action on 
Thrombosis and Disability (ECAT) study found CRP to be associated with increased risk of 
incident myocardial infarction or sudden cardiac death56.  The Multiple Risk Factor Intervention 
Trial (MRFIT) Study found an association between CRP and coronary heart disease mortality 
among a cohort of men considered high risk based on traditional cardiovascular risk factors59.  
The Iowa Rural Health Study found higher levels of CRP to be predictive of overall mortality in 
a sample of healthy, non-disabled older adults57.  Finally, the Healthy Aging, and Body 
Composition (HABC) study found CRP to be associated with incident congestive heart failure 
events55. 
1.5 SPECIFIC AIMS 
Cardiovascular disease, the leading cause of death in the United States, creates a major burden 
on the nation’s public health and economic sectors.  Although it is considered a widespread 
problem that can afflict anyone, certain subgroups are at an increased risk.  Two subgroups 
known to have a higher risk of cardiovascular disease than the general population are older 
adults and women transitioning through menopause.   
Atherosclerosis is considered to be a major contributor to the development of 
cardiovascular disease.  Inherent in its name, atherosclerosis is comprised of two components—
atheroma (thickening of the arteries caused by plaque buildup) and sclerosis (hardening of the 
arteries)60.  Subclinical markers of atherosclerosis including the ABI, which encompasses the 
atheroma component, and arterial stiffness, which encompasses the sclerotic component, are 
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important because they are inexpensive and noninvasive methods for measuring early vascular 
change that may predispose individuals to major cardiovascular disease.   
CRP, the prototypic downstream marker of systemic inflammation, is a major player in 
the atherosclerotic process.  Additionally, it has been shown to directly predict the incidence of 
cardiovascular events in several populations.  Several studies have examined the relationship 
between CRP and subclinical atherosclerosis but limitations in the current research exist.  One 
limitation is that the association between CRP and central arterial stiffness has not been 
extensively studied in women transitioning through menopause.  Another limitation is that no 
study has examined the association between CRP and distensibility, a measure of systemic 
arterial stiffness.  Finally, the association between CRP and incidence of subclinical PAD has not 
been thoroughly examined in an elderly cohort.  Thus, the specific aims of this dissertation are as 
follows: 
1. To investigate the cross-sectional association between CRP and carotid-femoral pulse 
wave velocity in a cohort of women transitioning through menopause 
2. To investigate the cross-sectional association between CRP and brachial artery 
distensibility in the same cohort listed above 
3. To investigate the association between CRP and incidence of subclinical PAD (assessed 
using the ABI) in an elderly cohort 
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2.1 ABSTRACT 
Arterial stiffness is associated with stroke, myocardial infarction, left ventricular hypertrophy, 
renal failure, and a host of other complications.  Increased levels of inflammatory markers, most 
notably C-Reactive Protein, have also been linked to cardiovascular outcomes.  Increases in both 
vascular stiffness and inflammation are known to occur with menopause.  Few studies have 
examined the relationship between C-reactive protein and arterial stiffness and these studies have 
not examined the association in women transitioning through menopause.   
The cross-sectional association between C-reactive protein and pulse wave velocity was 
evaluated in 154 middle-aged women enrolled in an ancilliary study to the Study of Women’s 
Health Across the Nation.  After adjustment for confounders, a one mg/L unit increase in 
continuous C-reactive protein was associated with a 0.8% increase in pulse wave velocity 
(p=.02).  C-reactive protein, analyzed as tertiles, was also associated with pulse wave velocity (p 
for trend=.014).  Stratification by menopausal status showed a strong association between 
continuous C-reactive protein and pulse wave velocity among post/late perimenopausal women 
(1.9%, p<.0001) but not among pre/early perimenopausal women (-0.41%, p=.33).  Categorical 
C-reactive protein was associated with pulse wave velocity in post/late perimenopausal women 
(p for trend=.0053) but not in pre/early perimenopausal women (p for trend=.76). 
C-reactive protein, whether analyzed continuously or categorically, was associated with 
aortic pulse wave velocity in post/late perimenopausal women but not in pre/early 
perimenopausal women.  This study provides a potential mechanism explaining the increased 
risk of cardiovascular outcomes in women transitioning through menopause.   
Key Words: Arterial Stiffness, C-reactive protein, Menopause, Atherosclerosis, 
Women’s Health    
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2.2 INTRODUCTION 
Aging of the arterial system involves both structural and functional changes in the arterial 
wall which leads to stiffening of the artery1.  Arterial stiffness is thought to contribute to the age 
associated increase in cardiovascular disease, morbidity, and mortality2,3.  Aortic pulse wave 
velocity (aPWV), assessed by carotid-femoral pulse wave velocity, is a simple, noninvasive, and 
highly reproducible measure of central arterial stiffness4.  In clinical populations, including 
patients with hypertension, diabetes, and end stage renal disease, aPWV is a predictor of 
cardiovascular and all-cause mortality5-8.  In addition, an association between aPWV and 
cardiovascular and overall mortality has been found in healthy older adults9. 
Inflammation is a major feature in the initiation and progression of atherosclerosis and 
subsequent cardiovascular disease10,11.  Several inflammatory markers exist but high sensitivity 
C-reactive protein (CRP) appears to be clinically advantageous because it is well-validated, 
inexpensive, and widely available12.  Prospective studies in clinical and healthy populations have 
shown a relationship between CRP and incidence of cardiovascular disease13-18.  In patients with 
unstable angina, CRP has been predictive of death, acute myocardial infarction, and rheumatoid 
arthritis19.  In healthy populations, CRP has been found to be associated with increased incidence 
of cardiovascular disease events including death due to coronary heart disease, nonfatal 
myocardial infarction, peripheral vascular disease, and stroke13-18.  On the basis of these results, 
the CDC has recommended the utility of CRP as a screening test for individuals at high risk of 
cardiovascular disease12.   
Menopause is a critical stage in a woman’s life associated with an increased incidence of 
cardiovascular disease20.  Reduced estrogen levels that accompany menopause may induce 
inflammation by increasing expression and secretion of proinflammatory cytokines21.  In 
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addition, decreased levels of estrogen may increase arterial stiffening by altering the 
collagen/elastin ratio within the arterial wall or by inhibiting smooth muscle cell 
proliferation22,23.  Both of these may present mechanisms for the increased risk of cardiovascular 
disease in women transitioning through menopause. 
Several studies have examined the relationship between inflammation and arterial 
stiffness but none have examined the influence of the menopausal transition on this relationship 
in a population-based cohort24-33.  Menopause may act as a trigger that strengthens the 
relationship between inflammation and arterial stiffness and thus provides a mechanism for the 
increase in cardiovascular disease seen after menopause.  The purpose of this study is to examine 
the effect of the menopausal transition on the association between CRP and aPWV.  This study 
will help to provide rationale for targeting middle-aged women to healthier lifestyle patterns 
aimed at reducing inflammation and arterial stiffening.   
2.3 METHODS 
2.3.1 Study Population 
The Study of Women’s Health Across the Nation (SWAN) is a multi-site, multi-ethnic 
longitudinal epidemiological study designed to examine the physical, psychological, and social 
changes that women experience during the menopausal transition.  At baseline, SWAN recruited 
a total of 3,302 women between the ages of 42 and 52 from seven clinical sites:  Boston, 
Chicago, Detroit, Los Angeles, Newark, Pittsburgh, and Oakland.  In order to be eligible for the 
study, women were required to have an intact uterus, at least one menstrual period and no use of 
reproductive hormones in the previous 3 months.  The institutional review boards of the 
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participating institutions approved this study, and all women signed informed consent forms 
before participation.   
Data from 154 women (97 Caucasian, 57 African American) enrolled in SWAN Heart, an 
ancillary study to SWAN, were used for the current analyses.  The ancillary project is a study of 
the natural history of subclinical atherosclerosis during the menopausal transition and involves 2 
out of the 7 SWAN sites (Pittsburgh and Chicago).  The study began at the time of the 4th and 5th 
annual SWAN exam and all participants were between 46 and 57 years of age.  Eligibility 
required that participants had no evidence of clinical atherosclerosis (MI, angina, intermittent 
claudication, cerebral ischemia, or revascularization), had not undergone a hysterectomy, and 
were not currently taking medication for hypertension, diabetes, or heart arrhythmias.  
Additional exclusion criteria for these analyses included missing information on CRP, aPWV, or 
menopausal status.  Among 222 women with a CRP measurement, 186 had an aPWV 
measurement.  An additional 32 women were excluded because their menopausal status could 
not be determined—primarily because they were on hormone therapy.  Among the 36 women 
without an aPWV measurement, 9 were due to technical complications and 27 were due to 
patient difficulty, unreadable files, or inability to measure the distance between the carotid and 
femoral recording sites. 
2.3.2 Cardiovascular Risk Factors 
The SWAN protocol required a fasting blood draw between days 2 and 5 of the menstrual cycle 
for measurements of reproductive hormones, lipids and lipoproteins, insulin, glucose, and 
clotting factors.  Blood samples were maintained at 40 C until separated and then frozen at -800 C 
and shipped on ice to Medical Research Laboratories, which is certified by the National Heart, 
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Lung and Blood Institute of the Centers for Disease Control34.  Total cholesterol and 
triglycerides were analyzed with the Hitachi 747 analyzer35 whereas high-density lipoprotein 
(HDL) cholesterol was isolated using heparin-2M manganese chloride36.  Low-density 
lipoprotein cholesterol (LDL) was calculated using the Friedwald equation37.  Plasma glucose 
was measured using a hexokinase-coupled reaction (Boehringer Mannheim, Indianapolis, In) and 
plasma insulin was measured using solid-phase radioimmunoassay procedure (DPC Coat-A-
Count, Los Angeles, CA).  Participants who satisfied at least 3 of the following 5 criteria were 
considered to have the metabolic syndrome:  abdominal obesity, hypertriglyceridemia, low HDL, 
hypertension, and impaired fasting glucose and diabetes.  CRP was assessed using the Behring 
Nephelometer II (hs-CRP on BN 100, Dade-Behring, Marburg, Germany).   
2.3.3 Hormones 
Hormone assays were conducted at the University of Michigan SWAN Endocrine Laboratory.  
FSH and estradiol (E2) assays were conducted using the ACS-180 automated analyzer.  Serum 
E2 concentrations were measured with a modified, off-line ACS-180 immunoassay.  Serum FSH 
concentrations were measured with a two-site chemiluminometric immunoassay using constant 
amounts of two monoclonal antibodies.  Testosterone concentrations were evaluated with the 
ACS-180 total testosterone assay modified to increase precision in the low ranges.  SHBG was 
measured using a competitive chemiluminescent assay.   
2.3.4 Physical Measures/Activity 
Two blood pressure measurements were averaged on the right arm after five minutes of rest in a 
seated position.  Height was measured using a stadiometer or portable stadiometer whereas 
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weight was measured using a balance beam, digital scale, or portable scale.  Body mass index 
(BMI) was calculated as weight in kilograms divided by height in meters squared.  Waist 
circumference was measured over undergarments or light clothing.  Leisure-time physical 
activity was measured with an adaptation of the questionnaire by Baecke38.   
2.3.5 Menopausal Status 
Information on menopausal status was collected using an annual interviewer administered 
questionnaire.  Premenopausal status was defined as having a menstrual period in the past three 
months with no change in cycle regularity in the past twelve months.  Early perimenopausal 
status was defined as having a menstrual period in the past three months with some change in 
cycle regularity in the past twelve months.  Late perimenopausal status was defined as not having 
a menstrual period in the past three months but having one in the past twelve months.  
Postmenopausal status was defined as not having a menstrual period in the past twelve months.  
Due to the small sample of premenopausal (n=8) and late perimenopausal (n=18) women, late 
perimenopausal women was combined with postmenopausal women and early perimenopausal 
women with premenopausal women to form a dichotomous menopausal status variable.     
2.3.6 Aortic Pulse Wave Velocity 
Aortic pulse wave velocity was measured as the distance between the carotid and femoral 
recording sites divided by the foot to foot time delay between the carotid and femoral 
waveforms.  The methodology has previously been described in detail39.  Briefly, aPWV was 
assessed by trained technicians using Doppler ultrasound of the right carotid and femoral 
arteries.  Participants were required to have 30 minutes of supine rest before measurement.  The 
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distance between the carotid and femoral recordings was measured using a standard tape 
measure over the surface of the body.  The time delay was calculated as the foot to foot time 
differential between simultaneously collected carotid and femoral wave forms, using the R-wave 
of the EKG.  Three runs were recorded for each participant and usable runs were averaged.  A 
greater pulse wave velocity is associated with a greater stiffening of the aorta.   
2.3.7 Statistical Methods 
Descriptive statistics (N, means/medians for continuous variables and percentages for categorical 
variables) for sociodemographic variables, anthropometric measures, lipids, blood pressures, 
hormones, fasting glucose, fasting insulin, metabolic syndrome, aPWV, and CRP were 
calculated.  Categorical variables were compared across the dichotomous menopausal status 
variable via Chi-square/Fishers exact test and continuous variables were compared via t-
test/Wilcoxon rank sum test.  Spearman correlations between risk factors and aPWV were 
calculated to understand basic associations and to determine candidate variables for multivariate 
models.  Multivariable linear regression was used to test the association between log transformed 
aPWV and continuous CRP while adjusting for confounders.  Stepwise regression was used to 
develop the most parsimonious model.  In order to facilitate the interpretation of the model, 
regression coefficients were exponentiated, thereby showing the relative or percent increase in 
aPWV with a one unit increase in CRP.  Due to the skewed nature of the variable, CRP was also 
analyzed as tertiles.  ANCOVA was used to test a trend in log aPWV across CRP tertiles (bottom 
tertile=0 to 1.3 mg/L, middle tertile=1.4 to 4.1 mg/L, top tertile > 4.1 mg/L) while adjusting for 
confounders.  Logarithmic mean aPWV values were backtransformed to the original scale to 
facilitate the interpretation of the results.  After final multivariable models were obtained, an 
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interaction term between CRP and  menopausal status was added to test whether or not the 
association between CRP and aPWV differed according to menopausal status.  Statistical 
significance was assessed using a type one error rate of 0.05.  Assumptions of linear regression 
(homoscedasticity, linearity, and normality of residuals) were tested to verify the validity of the 
model.  All analyses were done using SAS version 8.2. 
2.4 RESULTS 
Characteristics of the population stratified by menopausal status are presented in Table 2-1.  
Among the 154 women, 37.0% (n=57) were African American and 44.2% (n=68) were post/late 
perimenopausal.  The proportion of African Americans was similar according to menopausal 
status (p=0.40).  The mean age of the total population was 50.8 ± 2.6 and post/late 
perimenopausal women were significantly older than pre/early perimenopausal women.  In 
addition, total and LDL cholesterol, fasting glucose, and fasting insulin were all significantly 
greater in post/late perimenopausal women.  Estradiol and SHBG values were lower in post/late 
perimenopausal women and FSH was greater in this subgroup.  Although CRP and aPWV were 
higher in post/late perimenopausal women, the differences were not statistically significant. 
Women who were excluded from the analyses (n=68) were similar to women included in 
the analyses (n=154) in regards to all risk factors except the anthropometric measures and age. 
Women excluded from analyses had significantly (p<.05) less girth, weight, and BMI, and were 
significantly older than those women who were included.   
Table 2-2 displays the linear correlations between risk factors and aPWV within the full 
population and within each menopausal status group.  In the combined sample, all of the risk 
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factors were significantly associated with aPWV with the exception of the lipids, hormones, 
fasting glucose, and height.  Stratification by menopausal status showed that the majority of risk 
factors were more strongly associated with aPWV in post/late perimenopausal women than in 
pre/early perimenopausal women.   
Table 2-3 shows the results of multivariate models involving continuous CRP.  Notably, 
a one unit increase in CRP was significantly associated with a 0.8% increase in aPWV (p=.02).  
The interaction between CRP and menopausal status was significant (p<.0001) and the 
association between CRP and aPWV was stronger in post/late perimenopausal women (1.9%, p 
<.0001) than in pre/early perimenopausal women (-0.41%, p=.33).      
As depicted in Figure 2-1, the adjusted mean aPWV increased across CRP category (p for 
trend = 0.014). The interaction between categorical CRP and menopausal status was significant 
(p=.02) and this trend was primarily found in post/late perimenopausal women (Figure 2-2). 
Table 2-2 shows that certain risk factors were more strongly associated with aPWV in 
post/late perimenopausal women than in pre/early perimenopausal women.  In order to test 
whether these risk factors may attenuate the influence that status had on the relationship between 
CRP and aPWV, interaction terms between status and age, total cholesterol, LDL cholesterol, 
triglycerides, glucose, insulin, estradiol, FSH, SHBG, and testosterone were separately added to 
the model.  Among these, glucose and insulin were the only variables that attenuated the 
influence of menopausal status on the relationship between CRP and aPWV.  After the addition 
of an interaction term between insulin and menopausal status, the interaction between CRP and 
menopausal status was no longer significant (p=.16).  Likewise, after the addition of an 
interaction term between glucose and menopausal status, the interaction between CRP and 
menopausal status was no longer significant (p=.17).  
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When analyses were re-run excluding an additional 37 women with the metabolic 
syndrome, a one unit increase in CRP was associated with a 1.2% higher aPWV (p=.0071).  
However, the interaction between continuous CRP and status was no longer significant (p=.325).  
The association between categorical CRP and aPWV within this subgroup was only marginally 
significant (p for trend=.07) and the interaction between categorical CRP and menopausal status 
was not significant (p=.38). 
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Table 2-1.  Baseline Characteristics of the SWAN Heart Study Sample (Mean 
± Standard Deviation) 
 
 
 Full Group 
(N=154) 
Pre/E. 
Peri(N=68) 
L. Peri/Post 
(N=86) 
P-value 
for Status 
Difference 
Age (years) 50.8±2.6 49.7±2.0 52.3±2.5 <.0001 
Activity Index 2.47±0.68 2.49±0.61 2.44±0.77 0.72 
African American (%) 37.0 33.7 41.2 0.40 
     
Body Composition:     
Height (mm) 163.2±5.9 163.1±6.1 163.3±5.7 0.84 
BMI kg/m2 (kg/m2) 30.3±6.6 30.1±6.4 30.5±6.8 0.65 
Waist Circumference (cm) 91.1±15.1 90.3±15.7 92.1±14.4 0.46 
Weight (kg) 80.8±18.8 80.3±19.4 81.3±18.2 0.73 
    
Blood Pressure:     
Systolic Blood Pressure* 
(mmHg) 
118.0 (22.0) 118.0 (21.0) 118.0 (22.0) 0.83 
Diastolic Blood Pressure 
(mmHg) 
76.0±9.5 75.6±10.4 76.6±8.3 0.52 
Pulse Pressure (mmHg) 44.4±12.0 44.0±10.7 44.8±13.4 0.69 
    
Lipids:     
Total Cholesterol (mg/dL) 202.7±40.7 195.2±35.8 212.2±44.5 0.01 
LDL Cholesterol (mg/dL) 121.2±36.2 115.9±31.5 128.1±40.7 0.05 
HDL Cholesterol (mg/dL) 56.6±13.3 55.8±13.5 57.5±13.0 0.41 
Triglycerides* (mg/dL) 104.0 (62.0) 99.5 (62.0) 108.5 (71.0) 0.42 
    
Glucose Metabolism:     
Fasting glucose* (mg/dL) 90.0 (14.0) 88.0 (11.0) 93.0 (15.5) 0.04 
Fasting insulin* (uIU/mL) 10.3 (7.3) 9.0 (6.7) 11.8 (8.9) 0.01 
    
PWV* (cm/sec) 776.2 
(227.1) 
769.6 (213.7) 777.6 (233.8) 0.32 
C-Reactive Protein* 
(mg/L) 
2.3 (4.7) 2.1 (4.2) 2.9 (6.5) 0.11 
 
 
 
 
  * Values are median (Interquartile Range) 
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Table 2-2.  Relation of Cardiovascular Risk Factors and Aortic Pulse Wave Velocity 
(Unadjusted Spearman Correlation Coefficients) 
 
 Full Group (n=154) Pre/Early Peri 
(n=86) 
Post/Late Peri 
(n=68) 
Risk Factors Correlation
Coefficient 
P-
value 
Correlation
Coefficient 
P-
Value 
Correlation
Coefficient 
P-
value 
Age 0.27 .0007 0.24 .02 0.32 .007 
Activity Index -.23 .006 -0.13 .25 -0.30 .02 
       
Body Composition:       
Weight 0.24 .003 0.23 .04 0.25 .04 
Height 0.02 .78 0.06 .62 0.002 
BMI 0.23 .004 0.24 .03 0.22 .08 
Waist Circumference 0.27 .0009 0.24 .03 0.30 .01 
       
Blood Pressure:       
Systolic Blood Pressure 0.19 .02 0.16 .15 0.20 .09 
Diastolic Blood 
Pressure 
0.17 .04 0.12 .30 0.22 .07 
Pulse Pressure 0.16 .05 0.14 .21 0.18 .15 
      
Lipids:       
Cholesterol 0.15 .07 0.02 .84 0.24 .05 
LDL 0.14 .09 0.04 .73 0.21 .08 
HDL -0.14 .08 -0.05 .62 -0.22 .07 
Triglycerides 0.14 .08 0.01 .92 0.26 .03 
       
Glucose Metabolism:       
Fasting Glucose -0.05 .53 -0.19 .08 0.07 .60 
Fasting Insulin 0.18 .03 -0.03 .81 0.38 .002 
       
Inflammatory/ 
Hemostatic Markers: 
      
C-Reactive Protein 0.37 <.0001 0.25 .02 0.52 <.0001 
.99 
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Table 2-3.  Percent Increase in Aortic Pulse Wave Velocity for a One Unit Increase 
in CRP (mg/L) 
 
 Full Group Pre/Early Peri Post/Late Peri 
 Percent 
Increase 
P-value Percent 
Increase 
P-value Percent 
Increase 
P-value 
Unadjusted 1.2 .0004 0.26 .58 2.3 <.0001 
Adjusted* 0.8 .02 -0.41 .33 1.9 <.0001 
 
*Adjusted for age, systolic blood pressure, ethnicity, site, waist circumference, diastolic 
blood pressure, and physical activity; Status*CRP interaction P-value <.0001 
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Figure 2-1.  Adjusted* Mean Pulse Wave Velocity by CRP Tertiles† 
*Adjusted for age, systolic blood pressure, ethnicity, site, waist circumference, diastolic 
blood pressure, and Physical Activity; p-value for trend=.014 
†Bottom Tertile=0 to 1.3 mg/L; Middle Tertile=1.4 to 4.1 mg/L; Top Tertile > 4.1 mg/L 
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Figure 2-2.  Adjusted* Mean Pulse Wave Velocity by CRP Tertiles Stratified By 
Menopausal Status 
 
* Adjusted for age, systolic blood pressure, ethnicity, site, waist circumference, diastolic 
blood pressure, and Physical Activity; Status*CRP interaction  P-value= .02 
†P-Value for trend = 0.76 
‡P-Value for trend = .0053 
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2.5 DISCUSSION 
The primary finding of this study is that CRP is significantly associated with aPWV in a cohort 
of women transitioning through menopause and that this association is significantly stronger in 
women who are later in their transition than in women who are earlier in their transition. 
Several studies have looked at the association between inflammation and arterial stiffness 
but only a few have used CRP and aPWV to measure inflammation and arterial stiffness 
respectively24-27,29.  Among these studies, only one utilized a population based cohort but that 
study focused on older adults24.  The other studies examined the association in healthy 
individuals free of cardiovascular related problems, individuals with newly diagnosed 
hypercholesterolaemia, and individuals with systemic vasculitis25-27,29.  All of these studies found 
a strong positive association between CRP and aPWV.  Our study supports these findings and 
extends them by characterizing a differential association between CRP and aPWV according to 
stage of the menopausal transition. 
CRP was examined both as a continuous and categorical variable.  In both cases, CRP 
was associated with aPWV and the relationship was significantly stronger in post/late 
perimenopausal women.  Clinically defined cutpoints of CRPP12 were not used because a very 
small sample of the post/late perimenopausal women would be classified as low risk CRP (n=9).  
Thus, we would not expect to have the power to detect an interaction effect. 
Hormone therapy users were excluded from the analyses because of the inconsistent 
literature on the relationship of arterial stiffness and inflammation with hormone replacement 
therapy use40-43.  When hormone therapy users were added back into the analyses, the results 
were very similar to those obtained when excluding them. 
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Because CRP values greater than 10.0 mg/L can be indicative of acute inflammation, we 
re-ran analyses including women with CRP levels less than 10.0 mg/L (n=132).  Both continuous 
and categorical CRP were more strongly associated with aPWV in post/late perimenopausal 
women than in pre/early perimenopausal women. 
Several potential mechanisms could explain our findings.  There is evidence of an 
increase in the expression and secretion of proinflammatory cytokines (IL-1, IL-6, and TNF- α ) 
with a reduction in estradiol21.  CRP is known to be stimulated by these proinflammatory 
cytokines.  Increased inflammation due to estrogen deficiency could inhibit endothelium-
dependent vasodilation and synthesis of nitric oxide, a smooth muscle relaxant.  Increased 
inflammation could also adversely impact the collagen/elastin ratio of the vessel which could 
lead to increased stiffening24,25.  Estradiol also has cardioprotective effects which may be 
mediated by activation of the estrogen receptor-α and estrogen receptor-β.  These receptors could 
have direct vasodilatory effects on the vessels by activation of nitric oxide synthase and indirect 
effects on serum lipid concentrations, fibrinolytic, or inflammatory factors20,22.       
Another potential mechanism is that an increase in vessel diameter due to menopausal-
induced stiffening could lead to an increase in tensile stress which would make the vessel more 
susceptible to risk factors for increased inflammation.     
A third potential mechanism is that inflammation could indirectly impact arterial 
stiffening through its association with diabetes24, which is more prevalent among 
postmenopausal women than premenopausal women44.  Our results may lend some support to 
this theory because the addition of interaction terms between glucose and insulin with 
menopausal status diminished the interaction effect between CRP and menopausal status.  
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Additionally, exclusion of women with metabolic syndrome, which is known to be associated 
with diabetes, attenuated the interaction effect between CRP and menopausal status.      
Several limitations of our study exist.  Inherent in any cross-sectional design is the 
inability to determine causality.  Thus, it cannot be ascertained whether increased inflammation 
results in increased arterial stiffening or vice versa.  In addition, our relatively small sample size 
limited our capacity to further investigate the role of ethnicity on the findings.  Finally, due to the 
sample size, tripartite comparisons between premenopausal, perimenopausal, and 
postmenopausal women could not be made.   
This study is important because it explores a potential mechanism explaining the 
increased risk of cardiovascular outcomes in women who are later in their menopausal transition.  
It is likely that menopause is associated with an increase in inflammation, which in turn results in 
increased stiffening of the aorta and increased risk of cardiovascular outcomes.  Both 
inflammation and arterial stiffness have been linked to cardiovascular outcomes in clinical and 
healthy populations5-9,13-17.  In addition, there is evidence that inflammation and arterial 
stiffening can be tempered with certain medications, physical activity, and healthy lifestyles45-49.  
Therefore, it is likely that the menopause associated increase in cardiovascular risk can be 
alleviated or eliminated through lifestyle patterns aimed at reducing inflammation and arterial 
stiffening.   
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3.1 ABSTRACT 
The age associated increase in arterial stiffness is associated with a host of complications 
including stroke, myocardial infarction, diabetes, and atherosclerosis.  C-reactive protein, a 
marker of systemic inflammation, is a major player in the initiation and progression of 
atherosclerotic plaques.  Studies have found a positive relationship between C-reactive protein 
and arterial stiffness but these studies have focused on a localized region of the artery.  The 
Dynapulse 5000A presents a simple, inexpensive and noninvasive technique to measure systemic 
arterial stiffness that adjusts for artery size.  This study examined the association between C-
reactive protein and systemic arterial stiffness in a middle-aged cohort of women. 
The association between C-reactive protein and brachial artery distensibility, an indicator 
of systemic arterial stiffness, was evaluated in 1069 middle aged women enrolled in the Study of 
Women’s Health Across the Nation.  The mean age and distensibility of the population were 
53.6 (s.d = 2.6) and 6.2 (s.d = 1.2) respectively.  The ethnic distribution of the population was: 
African American (14.6%, n=156), Caucasian (54.0%, n=577), Chinese (11.6%, n=124), and 
Japanese (19.8%, n=212).  After adjustment for confounders, log transformed C-reactive protein 
was significantly associated with lower distensibility (β=-0.13, p=.0011).  The adjusted mean 
distensibility decreased with increasing tertiles of C-reactive protein (p for trend = .0031).  The 
association between C-reactive protein and distensibility did not differ by ethnicity or stage of 
the menopausal transition. 
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This study found a strong association between C-reactive protein and systemic arterial 
stiffness, measured by the brachial artery distensibility.  These results add to the existing 
literature by showing a relationship between inflammation and arterial stiffness independent of 
artery size.   
3.2 INTRODUCTION 
Central arterial stiffness is thought to contribute to the age associated increase in cardiovascular 
disease, morbidity, and mortality1,2.  It has been found to be associated with cardiovascular and 
all cause mortality in patients with hypertension, diabetes, and end stage renal disease3-6.  
Additionally, an association between central arterial stiffness and cardiovascular and overall 
mortality has been found in healthy older adults7.  Most of the studies have used aortic pulse 
wave velocity as the indicator of arterial stiffness.  A system called the Dynapulse 5000A 
calculates the brachial artery distensibility, a measure of systemic arterial stiffness.  The clinical 
advantage of distensibility over pulse wave velocity is that it is less expensive and easier to 
perform8.  Furthermore, aortic pulse wave velocity is a measure of central arterial stiffness 
whereas distensibility measures whole body arterial stiffness. 
Inflammation is a major feature in the initiation and progression of atherosclerosis9,10.  
Among the existing inflammatory markers, C-Reactive protein (CRP) appears to be clinically 
advantageous because it is well-validated, inexpensive, and widely available11.  Several 
prospective studies in a variety of populations have found a relationship between CRP and 
cardiovascular and overall mortality12-17.   
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Studies have found an association between CRP and aortic pulse wave velocity in healthy 
and clinical populations18-32.  However, aortic pulse wave velocity only represents the properties 
of large arteries but not the arterial system as a whole33.  Distensibility, on the other hand, is a 
measure of systemic arterial stiffness that is useful when comparing arteries of different size34.  
The Study of Women’s Health Across the Nation (SWAN) is a multi-site, multi-ethnic 
longitudinal epidemiological study designed to examine how various risk factors change during 
the menopausal transition.  The goal of the current study is to examine the cross sectional 
association between CRP and distensibility within this population.  This study will expand upon 
the current literature by exploring the relationship between inflammation and arterial stiffness 
independent of artery size.  Because structural and functional properties vary between arteries of 
different size, this study could identify a relationship between inflammation and arterial stiffness 
that is not restricted to the large central arteries. 
3.3 METHODS 
3.3.1 Study Population 
SWAN is a multi-site, multi-ethnic longitudinal epidemiological study designed to examine the 
physical, psychological, and social changes that women experience during the menopausal 
transition.  At baseline, SWAN recruited a total of 3,302 women between the ages of 42 and 52 
from seven clinical sites:  Boston, Chicago, Detroit, Los Angeles, Newark, Pittsburgh, and 
Oakland.  Participants self identified themselves into five ethnic groups including Caucasian, 
African American, Hispanic, Japanese, and Chinese.  Women who were Caucasian or a member 
of a designated ethnic group were enrolled at each site, including African American women at 
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Boston, Chicago, Detroit, and Pittsburgh, as well as Japanese, Chinese, and Hispanic women at 
Los Angeles, Oakland, and Newark respectively.  In order to be eligible for the study, women 
were required to have an intact uterus, at least one menstrual period and no use of reproductive 
hormones in the previous 3 months.  The institutional review boards of the participating 
institutions approved this study, and all women signed informed consent forms before 
participation. 
In SWAN, the Dynapulse measure was conducted at the 7th follow-up visit 
(approximately 7 years after the baseline visit).  Thus, all analyses in this study were conducted 
using data from this visit.  At visit 7, there were 2,320 women remaining in SWAN. 
3.3.2 Brachial Artery Distensibility 
The Dynapulse derived distensibility, defined as the percent change in a section of the artery per 
one mmHg change in pressure, is a noninvasive measure of vascular stiffness.  Lower values of 
distensibility represent stiffer arteries.  The Dynapulse system used a pulse dynamic pattern 
recognition methodology to determine distensibility from the oscillometric signal of a standard 
cuff sphygmomanometer.  Participants had a special blood pressure cuff placed around their 
upper arm after five minutes of rest to generate a pressure waveform.  This study used three cuff 
sizes (pediatric, normal, and adult) based on the participant’s arm circumference.  The pressure 
waveform was calibrated and incorporated into a physical model of the cardiovascular system, 
assuming a straight tube brachial artery and a T-tube aortic system.  Data from each clinic site 
was entered into a computer interfaced to the Dynapulse 5000A monitoring instrument (Pulse 
Metric, Inc., San Diego, CA).  Three measurements were performed sequentially for each 
participant (with a 5 minute resting period between measurements) and uploaded to the 
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www.dynapulse.com website directly from the monitoring instrument.  Analyses of the 
waveforms were conducted by Pulsemetric and hemodynamic parameters in addition to 
distensibility were calculated.  The formulas for calculating the distensibility parameter have 
been published and validated35.  Briefly, the distensibility is derived from a formula that  
incorporates the participant’s effective cuff width and brachial artery diameter, which is 
estimated using an empirically derived model based on gender, height, weight, and mean arterial 
blood pressure. 
In SWAN, the Dynapulse measure was completed on 1,347 women.  Reasons for not 
completing the measure included mechanical problems with the equipment (n=403), participant’s 
arm size exceeding the size of the largest cuff (n=228), participants being outside of the 3 month 
window for collection (n=98), participants being unable or unwilling to come to the clinic site 
(n=172), participants refusal (n=24), or other reasons (n=146).  Because of mechanical/technical 
problems, no measurements were completed at Newark or Detroit.  Since Hispanic women were 
only interviewed at Newark, this study only includes Caucasian, African American, Chinese, and 
Japanese women.  Measurements with unreadable waveforms (determined by Pulsemetric) or 
outside of the 25-35 second range for cuff deflation time (part of SWAN’s protocol) were 
considered unusable.  Among the women who completed the Dynapulse measure, 1,135 had at 
least one usable measurement.  An additional 66 women were excluded because they had a 
hysterectomy at some point during the study.  Thus, a total of 1069 women were used in the 
current analyses.  It should be noted that due to technical problems with obtaining the 
measurement on extremely heavy women (i.e. largest cuff size being too small for the woman’s 
arm), this sample is an under representation of the heavier women transitioning through 
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menopause.  Thus, any associations found with brachial artery distensibility would likely be an 
underestimate of the true association within this population. 
3.3.3 Cardiovascular Risk Factors 
The SWAN protocol required a fasting blood draw between days 2 and 5 of the menstrual cycle 
for measurements of reproductive hormones, lipids and lipoproteins, insulin, glucose, and 
clotting factors.  Blood samples were maintained at 40 C until separated and then frozen at -800 C 
and shipped on ice to Medical Research Laboratories, which is certified by the National Heart, 
Lung and Blood Institute of the Centers for Disease Control.  Total cholesterol and triglycerides 
were analyzed with the Hitachi 747 analyzer whereas high-density lipoprotein (HDL) cholesterol 
was isolated using heparin-2M manganese chloride.  Low-density lipoprotein cholesterol (LDL) 
was calculated using the Friedwald equation.  Plasma glucose was measured using a hexokinase-
coupled reaction (Boehringer Mannheim, Indianapolis, In) and plasma insulin was measured 
using solid-phase radioimmunoassay procedure (DPC Coat-A-Count, Los Angeles, CA).  CRP 
was assessed using the Behring Nephelometer II (hs-CRP on BN 100, Dade-Behring, Marburg, 
Germany).  Smoking status (current vs. not current) was self-reported. 
3.3.4 Physical Measures 
Two blood pressure measurements were averaged on the right arm after five minutes of rest in a 
seated position.  Height was measured using a stadiometer or portable stadiometer whereas 
weight was measured using a balance beam, digital scale, or portable scale.  Body mass index 
(BMI) was calculated as weight in kilograms divided by height in meters squared.  Waist 
circumference was measured over undergarments or light clothing. 
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3.3.5 Menopausal Status 
Information on menopausal status was collected using an annual interviewer administered 
questionnaire.  Premenopausal status was defined as having a menstrual period in the past three 
months with no change in cycle regularity in the past twelve months.  Early perimenopausal 
status was defined as having a menstrual period in the past three months with some change in 
cycle regularity in the past twelve months.  Late perimenopausal status was defined as not having 
a menstrual period in the past three months but having one in the past twelve months.  
Postmenopausal status was defined as not having a menstrual period in the past twelve months.  
Hormone therapy use was identified as current, former, and never.  Due to small sample sizes of 
premenopausal (n=29) and late perimenopausal (n=112) women, a dichotomous variable was 
created to combine early perimenopausal with premenopausal and late perimenopausal with 
postmenopausal women.   
3.3.6 Medication Use/Disease: 
Information on all medication use and diabetes status was based on the annual interviewer-
administered questionnaire.  Participants classified for medication use were required to be taking 
the respective medication twice a week for the past month at the time of the interview.  
Participants classified as having diabetes were told by a doctor that they had diabetes. 
3.3.7 Statistical Methods 
Descriptive statistics (N, means/medians for continuous variables and percentages for categorical 
variables) for sociodemographic variables, anthropometric measures, lipids, blood pressures, 
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fasting glucose, fasting insulin, distensibility and CRP were calculated.  Spearman correlations 
between risk factors and distensibility were calculated to understand basic associations and to 
determine candidate variables for multivariate models.  Stepwise multivariable linear regression 
was used to test the association between distensibility and log transformed CRP while adjusting 
for confounders.  In addition to CRP, fasting glucose, fasting insulin, and triglycerides were all 
log transformed.  Due to the skewed distribution of the variable, CRP was also analyzed as 
tertiles.  ANCOVA was used to test a trend in distensibility across CRP tertiles (Bottom 
Tertile=0 to 0.5 mg/L, Middle Tertile=0.6 mg/L to 1.7 mg/L, Top Tertile > 1.7 mg/L) while 
adjusting for confounders.  Interaction terms were added to the multivariate models to determine 
whether or not the association between CRP and distensibility differed by ethnicity or the stage 
of menopausal transition.  A Bonferroni post hoc multiple comparisons test was used to examine 
pairwise differences in mean distensibility between the CRP tertile groups.  Statistical 
significance was assessed using a type one error rate of 0.05.  Assumptions of linear regression 
(homoscedasticity, linearity, and normality of residuals) were tested to verify the validity of the 
model.  All analyses were done using SAS version 8.2. 
3.4 RESULTS 
Characteristics of the population are presented in Tables 3-1 and 3-2.  Among the 1069 women 
in the study, 54.0% (n=577) were Caucasian, 14.6% (n=156) were Black, 11.6% (n=124) were 
Chinese, and 19.8% (n=212) were Japanese.  The majority of women were postmenopausal 
(44.2%, n=473) while only 3% (n=29) were premenopausal.  The sample consisted of 171 (16%) 
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hormone therapy users.  The mean age of the population was 53.6 ± 2.6 years.  The mean 
distensibility was 6.2 ± 1.2 %/mmHg with values ranging from 2.9 to 12.0.     
Table 3-3 indicates that women who were excluded from the analyses (n=1251) had a 
worse cardiovascular profile than women included in the analyses (n=1069).  The excluded 
sample had a higher BMI and waist circumference, were taller, had higher SBP, pulse pressure 
and mean arterial pressure, had higher fasting glucose, fasting insulin, triglycerides, and CRP.  
The women who were excluded had significantly lower total cholesterol, LDL cholesterol, and 
HDL cholesterol than the women who were included in the analyses.  A smaller proportion of 
blacks were included in the analyses compared to all other ethnic groups combined (22% vs 
57%, p<.05).  A smaller proportion of smokers were included in the analyses compared to 
nonsmokers (38% vs 48%, p<.05).  
Table 3-4 shows that most risk factors were univariately negatively associated with 
distensibility.  The blood pressure and body composition variables showed the strongest 
correlations with distensibility.  CRP was negatively correlated with distensibility (r= -0.17, p 
<.0001).   
Linear regression models showed that log-transformed CRP was associated with 
distensibility in both unadjusted and adjusted models (Table 3-5).  Before adjustment for 
confounders, a one unit increase in log CRP was associated with 0.18 lower levels of 
distensibility (p<.0001).  After adjustment for age, ethnicity, study site, smoking status, 
menopausal status, medication use, glucose, triglycerides, and hormone use, a one unit increase 
in log CRP was associated with 0.13 lower levels of distensibility (P=.0011).  In addition to 
CRP, increasing age (β=-0.08, p < .0001), log transformed fasting glucose (β=-0.72, p = .03), and 
log transformed triglycerides (β=-0.22, p = .01) were all associated with lower distensibility after 
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adjustment for confounders.  Before adjustment for confounders, African American women had 
a significantly lower mean distensibility than Chinese women (5.95 vs. 6.39, p=.02).  After 
adjustment for confounders, there was no difference in mean distensibility between any of the 
ethnic groups.  There was no difference in mean distensibility between women in different stages 
of the menopausal transition before or after adjustment for confounders. 
Figure 3-1 shows that increasing CRP tertiles were associated with a decrease in adjusted 
mean distensibility (p for trend = .0031).  After adjustment for confounders, the mean 
distensibility for the bottom tertile was 5.90±0.37, the middle tertile was 5.85±0.37, and the top 
tertile was 5.56±0.37.  When looking at pairwise differences in mean distensibility between the 
CRP tertile groups, women in the bottom (p=.004) and middle tertiles (p=.006) of CRP had a 
significantly lower mean distensibility than women in the top tertile.  However, women in the 
bottom and middle tertiles did not significantly differ in distensibility. 
When stratifying by ethnicity, the association between log-transformed CRP and 
distensibility was similar in all ethnic groups (p for interaction = 0.92).  After excluding Chinese 
and Japanese women, there was still no interaction effect between log-transformed CRP and 
ethnicity (p for interaction = 0.80).  Additionally, the increasing trend in mean distensibility 
across CRP tertiles was similar across all ethnic groups (p for interaction = 0.92).  The 
association between log-transformed CRP and distensibility was similar in women who were 
later in their transition and women who were earlier in their transition (p for interaction = 0.73). 
When excluding women who had only 1 useable distensibility measurement (n=36) or 
greater than 3 useable distensibility measurements (n=39), continuous (p=.0006) and categorical 
CRP (p for trend=.003) remained strongly associated with decreasing distensibility.  When 
excluding women with the wrong cuff size used in the distensibility measurement (n=186), 
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continuous (p=.0003) and categorical (p for trend=.001) CRP remained strongly associated with 
decreasing distensibility. 
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Table 3-1.  Continuous Descriptive Statistics For Dynapulse Analysis 
 
 
 N Mean Std Dev Median Interquartile 
Range 
Age (years) 1069 53.6 2.6 53.4 4.1 
      
Body Composition:      
Height (mm) 1066 161.7 6.7 161.7 9.4 
BMI kg/m2 (kg/m2) 1064 26.3 5.2 25.4 7.0 
Waist Circumference 
(cm) 
1067 83.3 12.8 81.9 18.4 
Weight (kg) 1065 69.0 15.2 66.8 20.6 
     
Blood Pressure:      
Systolic Blood 
Pressure (mmHg) 
1064 114.7 14.7 113.0 19.0 
Diastolic Blood 
Pressure (mmHg) 
1064 73.3 9.1 73.0 12.0 
Pulse Pressure 
(mmHg) 
1064 41.4 10.9 40.0 13.0 
Mean Arterial 
Pressure (mmHg) 
1064 87.1 10.0 86.5 13.0 
     
Lipids:      
Total Cholesterol 
(mg/dL) 
1002 209.7 35.6 206.0 47.0 
LDL Cholesterol 
(mg/dL) 
978 124.0 32.5 120.0 41.0 
HDL Cholesterol 
(mg/dL) 
1001 61.9 15.4 60.0 22.0 
Triglycerides (mg/dL) 988 119.7 69.4 99.0 69.0 
     
Glucose Metabolism:      
Fasting glucose 
(mg/dL) 
998 89.5 15.5 87.0 12.0 
Fasting insulin 
(uIU/mL) 
918 10.6 6.7 9.0 5.4 
     
Brachial Artery 
Distensibility 
(%/mmHg) 
1069 6.2 1.2 6.1 1.6 
C-Reactive Protein 
(mg/L) 
947 1.8 2.0 1.0 2.2 
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Table 3-2.  Categorical Descriptive Statistics For Dynapulse Analysis 
 
 N % 
Ethnicity   
Blacks 156 14.6 
Caucasians 577 54.0 
Chinese 124 11.6 
Japanese 212 19.8 
Menopausal Status   
Pre 29 2.7 
E.Peri 280 26.2 
L.Peri 111 10.4 
Post 586 54.8 
Hormone Therapy Use   
Current 171 16.0 
Former 217 20.3 
Never 681 63.7 
Current Smoker 111 10.4 
Heart Medication 24 2.3 
Blood Pressure 
Medication 
175 16.4 
Insulin Medication 29 2.7 
Cholesterol Medication 101 9.5 
Told to have Diabetes by 
doctor 
37 3.5 
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Table 3-3.  Comparison of Dynapulse Excluded and Included Samples 
 
 
 Included Sample Excluded Sample  
 N Mean Median N Mean Median P-Value 
Age (years) 1069 53.6 53.4 1251 53.5 53.3 0.29 
Body 
Composition: 
       
Height (mm) 1066 161.7 161.7 994 162.8 162.8 0.0003 
BMI kg/m2 
(kg/m2) 
1064 26.3 25.4 990 31.5 30.4 <.0001 
Waist 
Circumference 
(cm) 
1067 83.3 81.9 997 94.9 92.6 <.0001 
Weight (kg) 1065 69.0 66.8 995 83.6 79.9 <.0001 
Blood Pressure:        
Systolic Blood 
Pressure (mmHg) 
1064 114.7 113.0 986 120.0 118.0 <.0001 
Diastolic Blood 
Pressure (mmHg) 
1064 73.3 73.0 984 73.5 73.0 0.52 
Pulse Pressure 
(mmHg) 
1064 41.4 40.0 984 46.4 45.0 <.0001 
Mean Arterial 
Pressure (mmHg) 
1064 87.1 86.5 984 89.0 88.0 <.0001 
       
Lipids:        
Total Cholesterol 
(mg/dL) 
1002 209.7 206.0 988 202.9 201.0 <.0001 
LDL Cholesterol 
(mg/dL) 
978 124.0 120.0 933 120.0 117.0 0.009 
HDL Cholesterol 
(mg/dL) 
1001 61.9 60.0 988 58.0 56.0 <.0001 
Triglycerides* 
(mg/dL) 
988 119.7 99.0 943 127.7 108.0 0.03 
       
Glucose 
Metabolism: 
       
Fasting glucose* 
(mg/dL) 
998 89.5 87.0 954 98.1 89.0 <.0001 
Fasting insulin* 
(uIU/mL) 
918 10.6 9.0 933 16.4 12.6 <.0001 
C-Reactive 
Protein* (mg/L) 
947 1.8 1.0 847 2.7 1.8 <.0001 
 
 
     *Comparisons are for median values 
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Table 3-4.  Relation of Cardiovascular Risk Factors and Brachial Artery 
Distensibility (Unadjusted Spearman Correlation Coefficients) 
 
Risk Factors Correlation
Coefficient 
P-value 
Age -0.15 <.0001 
   
Body Composition:   
Weight -0.17 <.0001 
Height 0.006 .84 
BMI -0.19 <.0001 
Waist Circumference -0.20 <.0001 
   
Blood Pressure:   
Systolic Blood Pressure -0.50 <.0001 
Diastolic Blood Pressure -0.21 <.0001 
Pulse Pressure -0.54 <.0001 
Mean Arterial Pressure -0.36 <.0001 
   
Lipids:   
Cholesterol -0.07 .03 
LDL -0.07 .03 
HDL 0.11 .0006 
Triglycerides -0.15 <.0001 
   
Glucose Metabolism:   
Fasting Glucose -0.14 <.0001 
Fasting Insulin -0.17 <.0001 
   
Inflammatory/ Hemostatic Markers:   
C-Reactive Protein -0.17 <.0001 
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Table 3-5.  Linear Regression Models Testing the Association Between Log-
Transformed CRP and Brachial Artery Distensibility 
 
 Regression Estimate 
(β) 
P-value 
Unadjusted -0.18 <.0001 
Adjusted* -0.14 .0004 
 
*Adjusted for age, ethnicity, site, smoking status, menopausal status, hormone therapy 
use, log transformed triglycerides, log tranformed fasting blood glucose, medications, and 
diabetes 
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Figure 3-1.  Adjusted* Mean Brachial Artery Distensibility by CRP Tertiles† 
* Adjusted for age, ethnicity, site, smoking status, menopausal status, hormone therapy 
use, triglycerides, fasting blood glucose, medications, and diabetes 
† Bottom Tertile=0 to 0.5 mg/L; Middle Tertile=0.6 to 1.7 mg/L; Top Tertile > 1.7 mg/L 
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3.5 DISCUSSION 
The primary finding of this study is that CRP was associated with distensibility in a cohort of 
healthy middle aged women.  This relationship persisted whether analyzing CRP as tertiles or as 
a log transformed continuous variable.   
Several studies have found a relationship between CRP and arterial stiffness in a variety 
of populations.  Two recent studies have shown CRP to be related to arterial stiffness in a cohort 
of untreated hypertensive patients19,28.  Another study found a number of acute phase proteins 
(including CRP) to be associated with arterial stiffness in patients with type 2 diabetes mellitus29.  
Several studies have shown a relationship between CRP and arterial stiffness in individuals with 
an elevated level of systemic inflammation25,27.  One study found CRP to be a significant 
positive predictor of increased large artery stiffness in subjects with the metabolic syndrome21.  
The Rotterdam Study found CRP to be associated with increased aortic stiffness in older adults18.  
Finally, two studies examining healthy individuals found a positive relationship between CRP 
and increased arterial stiffness22,32.  The current study is the first to examine the relationship 
between CRP and distensibility.   
The Dynapulse parameters have been validated in normotensive35, hypertensive36, and 
hemodialysis patients8.  Although the research examining the association between brachial artery 
distensibility and cardiovascular risk factors is limited, a few studies have found an association 
in healthy populations.  Researchers from the Bogulasa Heart Study found a strong negative 
association between blood pressure and distensibility and weaker associations between age and 
distensibility among healthy young adults37.  Additionally, they found that a clustering of 
cardiovascular risk factors was more strongly associated with a reduction in distensibility than a 
single risk factor alone38.  Budoff et al. found an association between decreased brachial 
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distensibility and higher levels of coronary calcification—indicating the role of distensibility in 
identifying patients with atherosclerotic burden39. 
There are several potential biological mechanisms that could link increased inflammation 
to increased arterial stiffness.  First, inflammation is known to impair endothelial functioning, 
which would result in a decreased bioavailability of nitric oxide40.  Nitric oxide is a vasodilator 
that controls smooth muscle relaxation, a functional property of elastic arteries.  Second, 
interleukin-6 and tumor necrosis factor α, two cytokines known to stimulate the synthesis of CRP 
by hepatocytes, may directly cause glomerular damage and loss of kidney function41,42.  Several 
studies have shown increased arterial stiffness in individuals with kidney failure as a result of 
smooth muscle cell calcification43.  Finally, inflammation could cause structural damage to the 
vessels by promoting defragmentation of the elastin fibers and increased deposition of the 
collagen fibers28.   
Because of known ethnic differences in CRP44, the present study examined whether or 
not the effect of CRP on distensibility differed by ethnicity.  The association between CRP and 
distensibility was similar across all ethnic groups within this population.  However, it must be 
noted that many of the heavier African American women in this study were excluded because of 
technical problems in obtaining an appropriately sized cuff. 
There are several limitations in the current study.  First, the cross-sectional design of the 
study prevents the determination of the direction of the association between CRP and 
distensibility.  Second, there is a definite bias effect such that the sample used in this study has a 
better cardiovascular profile than the excluded sample.  The main reason for this is the inability 
to obtain the distensibility measurement on very heavy women due to the arm size exceeding the 
largest available cuff.  Thus, conclusions based on the results of the current study are limited to 
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women with a generally healthier cardiovascular profile.  However, the associations between 
CRP and distensibility found in this study are probably an underestimate of the true association 
that would be found with a more representative sample.  Third, the SWAN protocol asked for 
exactly three measurements per woman.  Due to the fact that some oscillometric tracings were 
rejected by the Dynapulse software, some women had less than or greater than three 
measurements.  However, when excluding women with less than two or greater than three 
measurements, there was still a strong association between CRP and distensibility.  Fourth, due 
to technical issues, an incorrect cuff size was used on several women.  However, results were 
similar after excluding these women from the analyses.  Finally, the current study did not adjust 
for body size or blood pressure variables because they directly incorporated in the formula used 
to calculate distensibility.  Thus, adjustment for these parameters would likely result in an over 
adjustment. 
This study is unique because it explores the relationship between an established marker 
of inflammation and a new marker of systemic arterial stiffness.  Previous studies have found an 
association between inflammation and arterial stiffness but these studies were not able to 
establish an effect independent of artery size.  In fact, the majority of these studies only focused 
on the aorta.  Because of structural and functional differences between different arteries, this 
study can provide an early step in identifying CRP as a risk factor for atherosclerosis in different 
arterial beds.  Future prospective studies are needed to explore the nature and direction of this 
relationship in more detail.   
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4.0  C-REACTIVE PROTEIN IS ASSOCIATED WITH INCIDENT PERIPHERAL 
ARTERIAL DISEASE IN AN ELDERLY COHORT 
To Be Submitted to Atherosclerosis 
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4.1 ABSTRACT 
Peripheral arterial disease, an indicator of early atherosclerosis, is a highly prevalent disease 
among older adults.  Inflammation appears to play an important role in all stages of 
atherosclerosis.  Few studies have prospectively examined the association between inflammation 
and PAD and these studies have not looked at racial differences in the association. 
The association between three inflammatory markers (C-Reactive Protein, Interleukin-6 
and Tumor Necrosis Factor-alpha) and 3 year incidence of PAD was evaluated in 1918 older 
adults enrolled in the Health Aging, Body, and Composition study (HABC).  The mean age of 
the population was 73.4 (s.d = 2.8).  Approximately half of the population was male (48.1%, 
n=922) and a third was black (35.2%, n=675).  C-Reactive Protein was significantly associated 
with three year higher incidence of PAD after adjustment for confounders (Top Tertile vs 
Bottom Tertile Odds Ratio = 2.00; Middle Tertile vs Bottom Tertile Odds Ratio = 1.90).  
Furthermore, there was a significant interaction effect between C-Reactive Protein and ethnicity 
(p for interaction = .0047) such that the association between C-Reactive Protein and PAD was 
stronger in whites than in blacks.  Tumor Necrosis Factor-alpha and Interleukin-6 were not 
associated with incident PAD. 
High levels of C-Reactive protein were associated with a higher 3 year incidence of PAD 
in a population based elderly cohort.  Measures to reduce inflammation should be tested to 
determine if this can alleviate the burden of subclinical atherosclerosis within this population.   
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4.2 INTRODUCTION 
Peripheral arterial disease (PAD) is common in older adults and is a strong indicator of 
generalized atherosclerosis.  Because most individuals with PAD are asymptomatic1,2, the ankle-
brachial index (ABI) is a useful non-invasive measure of PAD and shown to predict 
cardiovascular disease and mortality3-7. 
Inflammation is a feature in the onset, development, and evolution of atherosclerotic 
lesions8,9.  Inflammatory markers, including C-reactive protein (CRP), Interleukin-6 (IL-6), and 
Tumor Necrosis Factor Alpha (TNF-α), have been found to be prospectively associated with 
cardiovascular outcomes in both clinical and healthy populations10-18. 
Few studies have examined the association between inflammatory markers and PAD and 
the results from these studies have been equivocal19-29.  Only one prospective study has 
examined the association between inflammation and ABI21 but this study focused on progression 
of PAD rather than incidence of PAD.  Because of the high prevalence in older adults and the 
long-term consequences associated with the disease, it is essential to discover modifiable risk 
factors strongly associated with PAD.  Given the treatment and prevention methods available to 
alleviate the burden of inflammation, it may provide a target for reducing the burden of PAD and 
subsequently cardiovascular disease. 
Prevalence rates of PAD have been shown to vary by ethnicity2,30 with blacks having a 
higher prevalence than Caucasians.  CRP has also been shown to vary by ethnicity with blacks 
having higher levels than whites31.  No study has looked at whether or not the association 
between CRP and incident PAD differs according to ethnicity. 
The purpose of this study is to prospectively examine the association between three 
inflammatory markers (CRP, IL-6, and TNF-α) and 3 year incidence of PAD in a population 
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based elderly cohort.  Furthermore, racial differences in the association between inflammation 
and incident PAD within this population can be evaluated.  The prospective nature of the study 
allows the evaluation of a temporal relationship between inflammation and PAD. 
4.3 METHODS 
4.3.1 Study Population 
Health ABC is a prospective investigation of interrelationships among health conditions, body 
composition, social and behavioral factors, and functional change in a population of well-
functioning black and white men and women between the age of 70 and 79.  Each of the two 
study sites, Pittsburgh, PA, and Memphis, TN, recruited participants from a list of Medicare 
beneficiaries between April 1997 and June 1998.  The goal of recruitment was to have a cohort 
of highly functional older people at baseline that was nearly balanced among men and women 
and white and black individuals.  Race status was obtained from the Health Care Financing 
Administration (now the Centers for Medicare and Medicaid Services) database; recruitment was 
at random among all age-eligible individuals within each stratum of race (black and white).  
Inclusion criteria were (1) ability to walk one quarter mile, climb 10 steps, and perform basic 
activities of daily living without difficulty; (2) absence of life-threatening  illness; and (3) plans 
to remain in the geographic area for at least 3 years.  The cohort enrolled 3075 participants who 
completed baseline evaluations, 42% of whom were black and 48% of whom were men. 
The Health ABC study measured ABI at baseline and at a 3 year follow-up visit.  
Because this study was examining incident PAD, participants with an ABI < 0.9 (indicative of 
PAD) at baseline were excluded.  Participants with an ABI > 1.5, a possible indicator of poorly 
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compressible arteries2, were also excluded.  Finally, participants who had peripheral 
revascularization were excluded.  Among the 3075 participants at baseline, 2873 had a measured 
ABI.  Among the 202 participants with a missing ABI, 1 was due to an amputated leg, 58 were 
due to an inability to locate the tibial artery, 10 were due to an ulceration, 67 due to an 
unoccludable artery, and 66 for other reasons.  An additional 86 participants were excluded 
because they had an ABI > 1.5 (n=35) or peripheral revascularization (n=51).  Thus, a total of 
2787 participants were included in the baseline analyses.  Among the participants with a 
measured ABI, 2438 had an ABI greater than 0.9 in both legs.  At the 3 year follow-up visit, 495 
participants who had an ABI measured at baseline did not have it measured.  Among these 
participants, 118 had died, 2 had an amputated leg, 8 were due to an inability to locate the tibial 
artery, 1 had an ulceration, 12 had unoccludable arteries, and 354 missed the clinic visit for other 
reasons.  Finally, an additional 25 participants were excluded because they had an ABI > 1.5 at 
the follow-up (n=4) visit or peripheral revascularization at baseline (n=21).  Thus, 1918 
participants were included in the longitudinal analyses (see Figure 4-1). 
4.3.2 Inflammatory Markers 
Measures of IL-6, TNF-α, and CRP were performed using ELISA kits from R&D Systems 
(Minneapolis, MN).  Detectable limits were 0.10 pg/ml for IL-6, 0.18 pg/ml for TNF-α, and 
0.007 mg/L for CRP.  Interassay coefficient of variation were determined by duplicate analyses 
of 150 specimens; 10.3, 8.0, and 15.8% for IL-6, CRP, and TNF-α, respectively.  Participants 
with CRP values greater than 10.0 mg/L (n=146) could represent cases of acute inflammation 
and were thus excluded from all analyses involving CRP. 
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4.3.3 Ankle-Brachial Index 
The ABI is a noninvasive procedure used to detect peripheral arterial disease, a condition in 
which atherosclerosis obstructs blood flow to the legs.  It was measured by a hand-held, 8-MHz 
Doppler probe placed directly over the artery and a conventional mercury sphygmomanometer.  
Two measurements were taken on the right brachial artery, the right posterior tibial artery, and 
the left posterior tibial artery.  First, the average brachial systolic blood pressure was determined.  
Next, the average right posterior tibial systolic blood pressure was determined.  Then, the 
average left posterior tibial systolic blood pressure was determined.  Finally, the ABI for each 
leg was calculated as the ratio of the average posterior tibial systolic blood (for the respective 
leg) to the average brachial systolic blood pressure.  Participants with a ratio of less than or equal 
to 0.9, in either leg, were considered to have a low ABI32. 
4.3.4 Outcome Definition 
Since ABI was measured at baseline and 3 year follow-up, we were able to examine the effect of 
inflammatory markers at baseline on incident PAD.  Participants who developed incident PAD 
were defined as having normal ABI (ABI between 0.9 and 1.5 in at least one leg) at baseline and 
low ABI (ABI less than 0.9 in the same leg) at the follow up visit with a minimum decline in 
ABI of 0.15.  A minimum value of 0.15 was determined by studies in clinical populations33-35.  
Participants who did not develop incident PAD were defined as either having normal ABI at 
baseline and normal ABI at the follow up visit or normal ABI at baseline and low ABI at the 
follow up visit with a less than 0.15 decline in ABI. 
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4.3.5 Covariates 
Information was collected at baseline on sociodemographic fators, lifestyle factors (smoking and 
drinking status), self-reported comorbid conditions (diabetes defined by use of hypoglycemic 
agents, self-report, fasting plasma glucose ≥ 126 mg/dl or an oral glucose tolerance test ≥ 200 
mg/dl; hypertension defined by either self-report plus use of antihypertensive medications, or 
measured SBP ≥ 140 or DBP ≥ 90; congestive heart failure, coronary heart disease, 
cerebrovascular disease, or myocardial infarction by self report).  Glucose, insulin, triglycerides 
total cholesterol, and HDL cholesterol were all measured by a colorimetric technique on a 
Johnson & Johnson Vitros 950 analyzer.  LDL cholesterol was calculated using the Fridewald 
equation.  Baseline blood draws were taken after an 8-h fast.  Samples were then aliquotted and 
stored at -800 C until analysis; all transportation was conducted on dry ice.  Medications were 
brought in by the participant and recorded.  Carotid-Femoral pulse wave velocity was assessed 
by Doppler probes placed at the carotid and femoral arteries. 
4.3.6 Statistical Methods 
All analyses were performed using SAS ver 8.2.  Low ABI, an indicator of PAD, was defined as 
an ABI < 0.9 for at least one leg.  Normal ABI was defined as an ABI between 0.9 and 1.5 for 
both legs.  Participants with an ABI > 1.5 in either leg were excluded from all analyses.  Chi-
squared/Fisher’s exact and t-test/Wilcoxon Rank Sum test were used to compare categorical and 
continuous baseline risk factors between those with and without baseline PAD.  Fisher’s exact 
test was used to compare the percent of participants who developed incident PAD between the 
top and bottom tertile of risk factors.  Additionally, this test was used to compare the percent of 
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participants who developed incident PAD between categories of dichotomous variables.  
Because of their skewed distribution, inflammatory markers were categorized into tertiles.  The 
tertile categories were as follows:  CRP (Bottom Tertile = 0.15 mg/L to 1.08 mg/L, Middle 
Tertile = 1.09 mg/L to 2.18 mg/L, Top Tertile = greater than 2.18 mg/L), IL-6 (Bottom Tertile = 
0.25 pg/ml to 1.333 pg/ml, Middle Tertile = 1.334 pg/ml to 2.190 pg/ml, Top Tertile= greater 
than 2.190 pg/ml), TNF-α (Bottom Tertile= 0.57 pg/ml to 2.65 pg/ml, Middle Tertile = 2.66 
pg/ml to 3.63 pg/ml, Top Tertile = greater than 3.63 pg/ml).  Multivariate logistic regression was 
used to analyze the independent association between tertiles of inflammatory markers and 
incident PAD while adjusting for confounders.  Odds ratios (with 95 % confidence intervals) 
were calculated to compare the odds of developing PAD for the highest two inflammatory 
marker tertiles relative to the lowest tertile.  An interaction between CRP and race was added to 
the model to test whether the association between CRP and incident PAD differed according to 
race.  The Hosmer-Lemeshow test was run to assess model fit. 
4.4 RESULTS 
Characteristics of the population stratified by baseline ABI status are presented in Tables 4-1 and 
4-2.  Among the participants at baseline, 13.6% (n=380) had low ABI.  The low ABI group was 
significantly older, had higher SBP, heart rate, hemoglobin a1c, fating glucose, pulse wave 
velocity, CRP, and IL-6 than the normal ABI group.  In comparison to the normal ABI group, 
the low ABI group had a higher percentage of blacks, smokers, participants with a history of 
stroke, coronary heart disease, congestive heart failure, and participants taking medication.  In 
addition, the low ABI group was less educated and had lower family income than the normal 
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ABI group.  After adjustment for race, gender, age, BMI, SBP, hemoglobin a1c, fasting glucose, 
income, pulse wave velocity, smoking status, and comorbidities, none of the inflammatory 
markers were associated with baseline PAD. 
The mean duration of study time was 3.03 years.  Among the participants with a 
measured baseline ABI between 0.9 and 1.5 in both legs (n=2407), 79.7% (n=1918) had a 
calculated follow up ABI that was less than 1.5 in both legs.  Within this group, 8.4% (n=162) 
developed incident PAD at the follow up visit.  Table 4-3 compares incidence of PAD between 
participants in the top and bottom tertiles of a given risk factor.  Participants in the top tertile of 
age, SBP, fasting glucose, hemoglobin, pulse wave velocity, and CRP had significantly higher 
frequency of incident PAD than participants in the bottom tertile of the respective risk factor.  
Furthermore, blacks, non-drinkers, participants with lower income, participants with 
comorbidities, and participants taking insulin had significantly higher frequency of incident PAD 
than their respective counterparts (Table 4-4). 
The baseline participants who were not included in the follow-up analyses (n=869) were 
significantly older, had higher SBP, hemoglobin a1c, fasting glucose, pulse wave velocity, CRP, 
IL-6, and TNF-α than those who were included in follow-up analyses (n=1918).  Participants 
who were highly educated, had higher family income levels, and did not smoke were more likely 
to be included in the follow-up analyses.  Additionally, a higher percentage of whites than blacks 
were included in the follow-up analyses. 
Table 4-5 shows results from the multivariate logistic regression models characterizing 
the association between baseline inflammatory marker tertiles and incident PAD.  CRP was 
univariately associated with incident PAD (Odds Ratio for Top Tertile  vs Bottom Tertile = 1.87; 
Middle Tertile vs Top Tertile = 1.67).  However, IL-6 and TNF-α were not significantly 
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associated with incident PAD.  CRP remained significantly associated with incident PAD after 
adjustment for confounders (Odds Ratio for Top Tertile vs Bottom Tertile = 2.00; Middle Tertile 
vs Bottom Tertile = 1.90).  In addition to CRP, male gender (p=.05), older baseline age (p=.009), 
higher baseline BMI (p=.04), higher baseline SBP (p=.001), and higher baseline hemoglobin a1c 
(p=.05) were all multivariately associated with incident PAD.  When restricting the sample to 
individuals without any history of cardiovascular disease, results did not change.  There was a 
significant interaction between race and CRP (p-value for interaction = .0047) such that CRP 
was associated with incident PAD in whites but not in blacks.  In whites, CRP was strongly 
associated with incident PAD (Odds Ratio for Middle Tertile vs Bottom Tertile = 3.94, Top 
Tertile vs Bottom Tertile = 5.41).  In blacks, CRP was not associated with incident PAD (Odds 
Ratio for Middle Tertile vs Bottom Tertile = 1.05, Top Tertile vs Bottom Tertile = 0.74).  Figure 
4-2 shows incidence of PAD across CRP tertiles stratified by ethnicity.  Among blacks, 
incidence of PAD did not differ by CRP (test of trend p-value = 0.68).  Among whites, incidence 
of PAD increased with increasing CRP tertiles (test of trend p-value = 0.0002).  When stratifying 
by gender, a similar trend was found among men and women.  However, due to small sample 
size, the interaction between CRP and ethnicity stratified by gender was not statistically tested. 
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 3075 Participants At 
Baseline 
2787 Participants With Baseline ABI < 
1.5and No Peripheral Revascularization 
At Baseline 
2407 Participants With 
Baseline ABI Between 
0.9 and 1.5 
1918 Participants With ABI < 1.5 At 
Follow-Up Visit and No Peripheral 
Revascularization At Baseline 
 
 
 
 
 
 
 
 
 
 
Figure 4-1.  Diagram of Participants In the Study 
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Figure 4-2.  Percent of Incident PAD by CRP Tertile and Race 
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Table 4-1.  Continuous Baseline Characteristics of the Health ABC Study Sample 
 
 
 Full Group 
(N=2787) 
Normal† 
ABI 
(N=2407) 
Low‡ ABI 
(N=380) 
P-value 
for 
Difference 
Age (years) 73.6±2.9 73.5±2.9 74.2±2.8 <.0001 
     
Body Composition:     
Height (mm) 1661.9±93.5 1662.8±93.5 1656.2±93.0 0.20 
BMI (kg/m2) 27.4±4.8 27.4±4.7 27.3±5.0 
Waist Circumference (cm) 99.5±13.2 99.5±13.3 99.1±13.0 0.59 
    
Blood Pressure:     
Systolic Blood Pressure 
(mmHg) 
135.4±20.6 134.3±19.8 142.9±23.4 <.0001 
Diastolic Blood Pressure 
(mmHg) 
71.4±11.7 71.4±11.6 71.8±12.0 0.50 
    
Lipids:     
Total Cholesterol (mg/dL) 203.2±38.6 202.8±38.4 205.7±39.6 0.18 
LDL Cholesterol (mg/dL) 121.8±34.8 121.2±34.7 125.8±35.0 0.02 
HDL Cholesterol* (mg/dL) 51.0 (21.0) 51.0 (21.0) 50.0 (19.0) 0.32 
Triglycerides* (mg/dL) 119.0 (76.0) 119.0 (76.0) 116.0 (76.0) 0.91 
    
Glucose Metabolism:     
Fasting glucose* (mg/dL) 94.0 (18.0) 94.0 (17.0) 97.0 (28.0) 0.0008 
Fasting insulin* (uIU/mL) 6.90 (5.40) 6.90 (5.40) 7.30 (5.6) 0.28 
    
Hemoglobin a1c  6.33±1.1 6.26±1.0 6.73±1.3 <.0001 
    
PWV* (cm/sec) 804.0 
(407.0) 
789.6 (398.2) 890.9 (444.0) <.0001 
Inflammatory Markers:     
C-Reactive Protein* 
(mg/L) 
1.58 (1.8) 1.52 (1.8) 1.82 (1.9) 0.005 
Interleukin-6 (pg/mL)* 1.80 (1.5) 1.76 (1.5) 2.19 (2.1) 0.0006 
Tumor Necrosis Factor 
Alpha (pg/mL)* 
3.16 (1.7) 3.14 (1.6) 3.27 (1.9) 0.12 
0.63 
 
 
 
 
 
  * Values are median (Interquartile Range) 
   † ABI between 0.9 and 1.5 for both begs 
 ‡ ABI less than 0.9 in at least one leg 
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Table 4-2.  Categorical Baseline Characteristics of the Health ABC Study Sample 
 
 
 Full Group 
(N=2787) 
Normal† ABI 
(N=2407) 
Low‡ ABI 
(N=380) 
P-value for 
Difference 
 N % N % N %  
Males 1334 47.9 1153 47.9 181 47.6 0.96 
Blacks 1123 40.3 895 37.2 228 60.0 <.0001 
        
Education:       <.0001 
< High School 666 24.0 542 22.6 124 32.8  
HS Grad 911 32.8 783 32.6 128 33.9  
Postsecondary 1202 43.3 1076 44.8 126 33.3  
        
Family Income:       <.0001 
< 10K 311 12.7 249 11.7 62 18.7  
10K-25K 947 38.6 800 37.7 147 44.3  
25K-50K 793 32.3 699 33.0 94 28.3  
>=50K 402 16.4 373 17.6 29 8.7  
Current Smoking 
Status  
278 10.0 201 8.4 77 20.3 <.0001 
Current Drinking 
Status  
1395 50.3 1235 51.5 160 42.6 .002 
        
Comorbidities:        
History of Stroke 197 7.2 152 6.4 45 12.2 <.0001 
History of CHD 423 16.0 329 14.4 94 26.3 <.0001 
History of 
Congestive Heart 
Failure 
34 1.3 24 1.0 10 2.8 0.009 
Diabetes 401 14.4 301 12.6 100 26.4 <.0001 
Hypertension 1202 48.3 985 45.9 217 63.3 <.0001 
        
Medication Use:        
ACE Inhibitors 411 14.8 327 13.6 84 22.2 <.0001 
Insulin Meds 94 3.4 68 2.8 26 6.9 <.0001 
Statins 362 13.0 296 12.3 66 17.4 0.008 
 † ABI between 0.9 and 1.5 for both begs 
‡ ABI less than 0.9 in at least one leg 
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Table 4-3.  Comparison of Incidence of PAD Between the Top and Bottom Tertiles 
of Risk Factors 
 
 
 Number (Percent) 
of Participants In 
Bottom Tertile 
Who Developed 
Incident PAD  
Number (Percent) 
of Participants In 
Top Tertile Who 
Developed Incident 
PAD  
P-Value For 
Difference 
Age 40 (6.5) 71 (10.8) 0.007 
    
Body Composition:    
Height  52 (8.2) 45 (7.1) 0.46 
BMI  62 (9.7) 58 (9.1) 0.78 
Waist Circumference  62 (9.7) 51 (8.0) 0.28 
   
Blood Pressure:    
Systolic Blood Pressure  36 (5.7) 84 (12.8) <.0001 
Diastolic Blood Pressure  47 (7.4) 64 (10.0) 0.11 
   
Lipids:    
Total Cholesterol  55 (8.8) 60 (9.5) 0.70 
LDL Cholesterol  51 (8.2) 60 (9.7) 0.43 
HDL Cholesterol 57 (8.9) 56 (8.7) 0.91 
Triglycerides 63 (9.8) 50 (7.8) 0.24 
   
Glucose Metabolism:    
Fasting glucose 46 (7.2) 70 (10.8) 0.03 
Fasting insulin 55 (9.2) 47 (8.0) 0.47 
   
Hemoglobin a1c  35 (5.3) 72 (12.3) <.0001 
   
PWV 20 (3.8) 61 (11.5) <.0001 
Inflammatory Markers:    
C-Reactive Protein 35 (5.8) 63 (10.3) .0043 
Interleukin-6  49 (8.1) 62 (10.2) 0.20 
Tumor Necrosis Factor 
Alpha  
46 (7.7) 51 (8.6) 0.67 
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Table 4-4.  Comparison of Incidence of PAD Between Categorical Risk Factors 
 
 
 Number Who Developed 
Incident PAD 
%  Who Developed 
Incident PAD 
P-Value 
Gender   0.74 
Males 80 8.7  
Females 82 8.2 
Race   <.0001 
Blacks 85 12.6  
Whites 77 6.2  
Education   0.05 
< High School 43 10.7  
Postsecondary 66 7.4  
Income   <.0001 
<10 K 26 14.4  
> 50 K 11 3.4  
History of Stroke   0.03 
Yes 22 13.0  
No 140 8.0  
History of Diabetes   0.03 
Yes 28 12.6  
No 134 7.9  
History of 
Hypertension 
  0.007 
Yes 75 9.9  
No 60 6.2  
Smoker at Baseline   
Yes 16 11.5  
No 146 8.2  
Drinker at Baseline   0.001 
Yes 66 6.5  
No 96 10.7  
 
0.20 
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Table 4-5.  Odds Ratios (95% C.I.) Describing the Associations Between 
Inflammatory Markers and Incident PAD 
 
 Unadjusted Adjusted* 
CRP Tertile   
    Bottom (reference) 1.00 1.00 
    Middle 1.67 (1.02,2.58) 1.90 (1.07,3.38) 
    Top 1.87 (1.22,2.89) 2.00 (1.10,3.62) 
IL-6 Tertile   
    Bottom (reference) 1.00 1.00 
    Middle 0.91 (0.60,1.38) 0.78 (0.44,1.38) 
    Top 1.30 (0.87,1.92) 1.00 (0.58,1.71) 
TNF-α Tertile   
    Bottom (reference) 1.00 1.00 
    Middle 1.27 (0.84,1.90) 0.93 (0.55,1.59) 
    Top 1.12 (0.74,1.70) 0.76 (0.43,1.32) 
 
*Adjusted for Race, Gender, Age, SBP, Baseline ABI, Time Since Baseline, Hemoglobin a1c, 
Glucose, BMI, Pulse Wave Velocity, Baseline Smoking History, Baseline Family Income Status, 
and Comorbidities (History of Diabetes, History of Stroke, History of Myocardial Infarction, 
History of Congestive Heart Failure, History of Coronary Heart Disease) 
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4.5 DISCUSSION 
This study examined the association between three baseline inflammatory markers (CRP, IL-6, 
and TNF-α) and development of PAD after 3 years in a healthy elderly population.  The primary 
finding of this study is that CRP was associated with the development of incident PAD.  
Furthermore, the association was stronger in whites than blacks.  On the other hand, IL-6 and 
TNF-α were not associated with the development of PAD. 
Several studies have looked at the cross-sectional association between IL-6, CRP, and 
TNF-α with PAD and findings have been equivocal19,20,22-24,27-29,36,37.  McDermott et al showed 
that participants with PAD had higher levels of IL-6 (1.65 vs 1.37 pg/mL, p=.026) and CRP 
(3.18 vs 2.56 mg/dl, p=.043) compared to those without PAD20.  In another study, Mcdermott et 
al. found CRP to be inversely associated with ABI in patients without cardiac or cerebrovascular 
disease but not in patients with clinically evident cardiac or cerebrovascular disease19.  Yu et al.22 
found CRP to be associated with PAD in diabetic patients.  However, this group did not find a 
significant relationship between IL-6 and PAD.  A few studies have confirmed no relationship 
between TNF-α and PAD28,37.  Although there is extensive literature on the cross-sectional 
association between inflammation and PAD, there have only been a few prospective 
investigations examining this association21,25,26.  Furthermore, only one of these studies21 used 
ABI as an indicator of PAD, which would capture the asymptomatic cases.  However, this study 
measured ABI continuously and thus focused more on progression than incidence of PAD.  
Another limitation of this study was its inability to examine ethnic differences in the association. 
The incidence of PAD after 3 years of follow-up in this population was 8.4% which is 
consistent with another study looking at older adults38.  ABI decline was defined as the 
difference between ABI at baseline and 3 year follow-up in the same leg.  Incident PAD was 
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defined as a decline in ABI (from baseline to follow-up) to 0.9 of at least 0.15, a value derived 
from clinical populations33-35.   
In the present study, neither IL-6 nor TNF-α were associated with incident PAD.  One 
prospective study found IL-6 to be a stronger predictor than CRP of atherosclerotic 
progression21.  However, another study found CRP and not IL-6 to be associated with PAD in 
diabetic patients22.  Other studies have not found IL-6 and TNF-α to be increased in patients 
affected by uncomplicated PAD28,37.  It could be theorized that IL-6 and TNF-α act at a later 
stage in the atherosclerotic process and more involved in progression and rupture of the lesion.  
Given the age range within this study, any relationship between IL-6 and PAD could be 
confounded by diabetes. 
Contrary to one study23, this study found that the association between CRP and incident 
PAD was stronger in whites than in blacks.  This is not surprising for an elderly population since 
many other risk factors could contribute to the development of PAD among blacks.  Thus, any 
effect of CRP would be washed out by confounders. 
There are a number of potential biological mechanisms whereby CRP could lead to the 
development of PAD.  There is evidence of a direct role for CRP at all stages of the 
atherosclerotic process.  CRP has been shown to influence vascular vulnerability directly by a 
variety of mechanisms, including enhanced expression of local endothelial cell surface adhesion 
molecules39, monocyte chemoattractant protein-139, endothelin-140, and endothelial plasminogen 
activator inhibitor-141.  CRP has also been shown to be associated with reduced endothelial nitric 
oxide bioavailability40, increased tissue factor induction42, and increased LDL uptake by 
macrophages43. 
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The present study has several limitations.  First, the inflammatory markers were only 
measured at one time point.  This precludes examining how change in inflammatory markers 
influence incidence of PAD.  Second, the follow-up visit was three years after the baseline visit.  
This may prevent us from picking up a substantial number of cases who would eventually 
develop PAD.  Third, the leg used to define incident PAD was not consistent between 
individuals.  At least one study showed differences in ABI between legs but this study not 
ascertain whether or not decline in ABI differed by leg44.  Fourth, this study included some 
participants with symptoms of intermittent claudication and thus did not completely separate 
asymptomatic from symptomatic PAD.  Fifth, the observational nature of this study limits some 
of the conclusions that could be made concerning the direction of the relationship between 
inflammation and PAD.  A randomized clinical trial may be necessary to prove that treatment 
methods aimed at reducing inflammation will also reduce the incidence of PAD.  Finally, 
conclusions based on ethnic differences must be made with caution because of the small sample 
size.  However, the differences in odds ratios between ethnic groups were so overwhelming that 
we believe the estimates are valid. 
In conclusion, CRP was associated with 3 year incident PAD in a population based 
elderly cohort.  Furthermore, the association was much stronger in whites than in blacks.  This 
study did not find any relationship between IL-6 or TNF-α on 3 year incidence of PAD.  The 
primary significance of this study is that it provides the first prospective analysis of inflammation 
on incidence of PAD, defined by clinically derived cutpoints of the ABI.  Given the high 
prevalence of PAD in the elderly population and its strong association with cardiovascular 
outcomes, reducing inflammation may be a useful method for reducing the burden of 
cardiovascular disease in the elderly. 
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5.0  OVERVIEW OF DISCUSSION 
The following chapter will summarize the results from chapters 2 through 4, identify the 
strengths and limitations of this research, suggest future avenues of research, and describe the 
public health significance of the study. 
Cardiovascular disease is the leading cause of death in the United States.  Older adults 
and postmenopausal women have an increased risk of developing cardiovascular disease 
compared to the general population.  In 2002, approximately 70% of deaths attributed to some 
form of cardiovascular disease occurred in individuals over the age of 751.  Statistics show that 
women on average develop cardiovascular disease ten to fifteen years later in life than men—a 
pattern thought to be attributed to menopause2.   
Most forms of cardiovascular disease are caused by atherosclerosis3.  Subclinical markers 
of atherosclerosis are important in detecting early vascular changes that may predispose 
individuals to clinical cardiovascular disease.  Thus, it is important to identify and understand 
risk factors that are associated with subclinical atherosclerosis in subgroups at an increased risk 
of developing cardiovascular disease.   
In recent years, CRP has been firmly established as a cardiovascular risk factor  and has 
been linked to a myriad of outcomes including clinical cardiovascular disease, type 2 diabetes, 
hypertension, and renal disease4.  Although a plethora of studies have examined the association 
between CRP and clinical cardiovascular events, research looking at the association between 
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CRP and subclinical atherosclerosis has been scarce (see Appendices for the full literature 
review). 
The purpose of this dissertation was to examine the association between CRP and 
subclinical markers of atherosclerosis in two distinct population based cohorts.  The first part of 
the dissertation (Chapters 2 and 3) focused on delineating the cross-sectional relationship 
between CRP and arterial stiffness, an indicator of the sclerotic component of atherosclerosis, in 
a cohort of women transitioning through menopause.  The second part of the dissertation 
(Chapter 4) characterized the prospective association between CRP and subclinical PAD, an 
indicator of the atheroma component of atherosclerosis, in an elderly cohort.   
5.1 INFLAMMATION AND ARTERIAL STIFFNESS 
Several studies have found an association between CRP and central arterial stiffness but none 
have thoroughly examined this association in women transitioning through menopause.  In the 
first analysis (Chapter 2), it was hypothesized that higher levels of CRP would be associated with 
higher central arterial stiffness, assessed by carotid-femoral pulse wave velocity.  This analysis 
also examined whether or not the aforementioned association differed according to the woman’s 
stage of menopausal transition.  The primary finding from this analysis was that higher levels of 
CRP (examined both continuously and categorically) were significantly associated with higher 
levels of pulse wave velocity and this association was stronger in women later in their 
menopausal transition than women earlier in their menopausal transition.  Women classified as 
“late in their menopausal transition” were defined as not having a menstrual bleed in the three 
month prior to the start of the study whereas women classified as “early in their transition” were 
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defined as having a bleed in the three months prior to the start of the study.  Although CRP levels 
were greater in women who were later in their transition compared to women earlier in their 
transition, the difference was not statistically significant.  A previous study in this cohort showed 
an increase in CRP with hormone therapy use5.  However, they did not find an association 
between CRP and endogenous levels of estradiol.  Another study found evidence of an increase 
in expression and secretion of proinflammatory cytokines (IL-1, IL-6, and TNF- α ), which are 
thought to promote the synthesis of CRP by the liver6, with a reduction in endogenous estradiol7.  
More research is needed to explain why CRP may be differentially associated with exogenous 
and endogenous estrogens.  Because of the skewed distribution of the variable, CRP was 
examined as tertiles and as a logarithmically transformed variable.  The results were consistent 
regardless of how CRP was examined—further strengthening the findings.  Previous studies 
looking at the association between CRP and arterial stiffness have used clinically defined 
cutpoints for CRP (low risk=0 to1 mg/L, moderate risk=1 to 3 mg/L and high risk > 3.0 mg/L)8.  
However, more recent studies have promoted categorization into tertiles because of the lack of 
generalizability associated with the clinically defined cutpoints9. 
Several biological mechanisms could support the findings from this study.  First, 
increased inflammation due to estrogen deficiency could inhibit the synthesis of the smooth 
muscle relaxant nitric oxide.  Estradiol has cardioprotective effects which may be mediated by 
activation of the estrogen receptor-α and estrogen receptor-β, both of which are thought to have 
vasodilatory effects10,11.  Studies have shown that enzymes responsible for the synthesis of nitric 
oxide are associated with reduced arterial stiffness12.  These studies have also found an 
association between nitric oxide inhibitors and increased arterial stiffness12.  A second potential 
mechanism is that an increase in vessel diameter due to menopausal-induced stiffening could 
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make the vessel more susceptible to risk factors associated with increased inflammation.  Third, 
because diabetes is more prevalent among postmenopausal women than premenopausal 
women13, it could act as an indirect mechanism explaining the strong association CRP and pulse 
wave velocity in women who were later in their transition.  Our results seem to support this 
theory because the addition of interaction terms between glucose and insulin with menopausal 
status diminished the interaction effect between CRP and menopausal status.  Furthermore, 
exclusion of women with metabolic syndrome, which is known to be associated with diabetes, 
attenuated the interaction effect between CRP and menopausal status.  It isn’t clear whether 
diabetes would act as a confounder or component of the mechanism linking CRP with increased 
central arterial stiffness.  However, a number of studies seem to indicate that CRP may be a risk 
factor as opposed to a risk marker for diabetes14-17—a fact that would implicate diabetes as part 
of the mechanism. 
In the second analysis (Chapter 3), it was hypothesized that higher levels of CRP would 
be associated with higher systemic arterial stiffness, defined by a lower distensibility.  Research 
looking at distensibility and cardiovascular risk are limited and no previous study has explored 
the association between CRP and distensibility.  Distensiblity, defined as the percent change in 
the cross-sectional area of the artery per change in pressure, was measured by the Dynapulse 
5000A monitoring instrument (Pulse Metric, Inc., San Diego, CA).  The Dynapulse instrument 
used a pulse dynamic pattern recognition methodology to determine distensibility from the 
oscillometric signal of a standard blood pressure cuff.  The pressure waveform that was 
generated from the cuff was calibrated and incorporated into a physical model of the 
cardiovascular system, assuming a straight tube brachial artery and a T-tube aortic system.  The 
formula for calculating distensibility incorporated the participant’s effective cuff width and 
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brachial artery diameter, which was estimated using an empirically derived model based on 
gender, height, weight, and mean arterial blood pressure.  Consequently, distensibility provided a 
measure of systemic arterial stiffness that inherently controlled for body size, arterial size, and 
arterial pressure. 
The primary finding from the second analysis was that higher levels of CRP were 
associated with lower levels of distensibility in a cohort of women transitioning through 
menopause.  This finding persisted whether CRP was analyzed continuously or categorically.  
The association between CRP and distensibility did not significantly differ according to the stage 
of the menopausal transition.  In light of the findings from the first study, this result is surprising.  
The measurement of distensibility in SWAN was conducted at a later stage in the study than 
carotid-femoral pulse wave velocity.  Therefore, there was a relative increase in postmenopausal 
and decrease in premenopausal women in the second analysis compared to the first.  Among the 
women who were considered late in their transition, a greater proportion were postmenopausal in 
the second analysis compared to the first (n=586, 86% vs n=68, 79%).  There is at least some 
evidence that cardiovascular risk in women is greater during perimenopause than 
postmenopause18.  Thus, women who were defined as late in their transition in the second 
analysis may have in fact been healthier than the same group of women in the first analysis.     
Because of the cross-sectional nature of this study, we can only speculate on the potential 
biological mechanisms linking CRP to systemic arterial stiffness.  Interleukin-6 and tumor 
necrosis factor α, two cytokines known to stimulate the synthesis of CRP by hepatocytes, may 
directly cause glomerular damage and loss of kidney function19-21.  Several studies have shown 
increased arterial stiffness in individuals with kidney failure as a result of smooth muscle cell 
calcification22.  Inflammation could also cause structural damage to the vessels by promoting 
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defragmentation of the elastin fibers and increased deposition of the collagen fibers.  We are not 
able to speculate whether or not CRP may have a differential affect on different sites of the 
arterial wall.  Central and peripheral arteries are known to have different structural and 
functional properties and established risk factors are known to act differentially on their vessel 
walls23,24.  Further research is needed to explore the mechanisms linking CRP to arterial stiffness 
in different vascular beds. 
5.2 INFLAMMATION AND PERIPHERAL ARTERIAL DISEASE 
In the third analysis it was hypothesized that increased levels of baseline CRP would be 
associated with increased three year incidence of PAD in a cohort of older adults.  This study 
also examined the relationship between two pro-inflammatory cytokines (IL-6 and TNF-α) and 
incident PAD.  The ABI, a noninvasive measure of PAD, was calculated at baseline and a three 
year follow-up visit and incidence of PAD was based on a clinically derived formula confirmed 
from previous research25.  The prevalence of PAD at baseline was 14% and the three year 
incidence of PAD was approximately 8%.  Similar percentages have been found in other elderly 
cohorts25.  Participants in the top tertile of CRP had approximately two times the odds of 
developing PAD compared to participants in the bottom tertile.  IL-6 and TNF-α, cytokines 
responsible for the synthesis of CRP by hepatocytes, were not significantly associated with 
incident PAD.  Because of known ethnic differences in CRP26, we tested whether or not the 
association between CRP and PAD differed by ethnicity.  We found the association to be much 
stronger in whites than blacks and this pattern persisted after additional stratification by gender.  
A previous study discovered the cross-sectional association between CRP and PAD to be 
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stronger in blacks than whites—a finding that contradicted our results27.  However, their 
population was younger and the prevalence of PAD (4.9%) was consequently much lower.  In 
our population, it could be hypothesized that other risk factors contributed more to the 
development of PAD among blacks than whites.  Thus, any effect of CRP may have been 
washed out by the other risk factors among the blacks but not whites.  Although the analyses 
adjusted for these risk factors, there may have been an additive effect that we were unable to 
statistically control for.  Surprisingly, IL-6 and TNF-α were not associated with increased 
incidence of PAD.  Previous studies looking at these associations have produced conflicting 
results28-31.  It could be hypothesized that CRP was the only inflammatory marker sensitive 
enough to predict PAD in an older population with a high burden of disease.   
There are a number of potential mechanisms that could link CRP to the development of 
PAD.  PAD has been found to be associated with reduced levels of physical activity32,33 and 
lower levels of physical activity are associated with increased inflammation34.  It is unclear 
whether physical activity acts as a confounder or is directly involved in the mechanism linking 
CRP with PAD.  We would speculate that CRP is associated with increased PAD resulting in a 
reduction of physical activity and further increase in inflammation.  CRP has also been shown to 
act directly at all stages of the atherosclerotic process.  Expression of adhesion molecules by 
endothelial cells, the first major step in the atherosclerotic process, is induced by CRP.  Studies 
have implicated CRP as an activator of complement35-37 and stimulator of tissue factor 
production38,39, both of which are associated with PAD40,41.  CRP has also been found to be 
associated with an increased uptake of oxidized LDL by macrophages42.  A previous study found 
the macrophage uptake of oxidized LDL to be higher in patients with PAD compared to 
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controls43.  CRP appears to be associated with reduced endothelial nitric oxide bioavailability44, 
which is linked to increased PAD45. 
In summary, the three analyses conducted as part of this dissertation all showed a strong 
association between higher levels of systemic inflammation and increased subclinical 
atherosclerosis in two distinct populations at increased risk of developing cardiovascular disease.  
The following section aims to identify limitations in the current study and possible avenues of 
future research. 
5.3 LIMITATIONS/FUTURE RESEARCH--ANALYSES 1 AND 2 
There are a number of existing limitations in the first two analyses that support the need for 
future research.  The analyses both utilized a cross-sectional study design.  Thus, the direction of 
the association between CRP and arterial stiffness could not be tested.  To our knowledge, no 
study has prospectively examined the association between CRP and arterial stiffness and future 
research should focus on generating more longitudinal studies in this area.  Furthermore, studies 
that examine within woman change in the menopausal transition could more accurately 
distinguish the effects of age and menopause on the association between CRP and arterial 
stiffness. 
Although we selected a high risk subgroup for cardiovascular disease, the results may not 
have been representative of the general population of women transitioning through menopause 
because women with clinical cardiovascular disease were excluded.  However, both analyses 
found that levels of fasting glucose and insulin, total cholesterol, and LDL cholesterol were 
higher in the women who were later in their transition compared to women who were earlier in 
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their transition.  In the second analysis, systolic blood pressure and mean arterial pressure were 
also higher in women who were later in their transition than women who were earlier in their 
transition.  This provided evidence that the women who were later in their transition had an 
inferior cardiovascular risk profile than women who were earlier in their transition. 
The method used for classifying menopausal status presented another limitation.  The 
variables for menopausal status were all derived from an annual interviewer administered 
questionnaire and based on the participants most recent menstrual bleed date.  Although this may 
have increased the likelihood of recall bias, it is the most feasible way of deriving menopausal 
status in large population based cohort studies.    Another limitation with the classification of 
menopausal status was that duration of time spent within a status category was not considered.    
Future studies need to examine whether or not the cumulative time spent in a given menopausal 
status category influences the association between CRP and arterial stiffness. 
Both analyses either controlled for or excluded hormone therapy users in the multivariate 
models.  There was insufficient power to detect whether or not hormone therapy use impacted 
the association between CRP and arterial stiffness.  There has been a great deal of controversy on 
the effect of hormone therapy use on cardiovascular risk.  Observational studies in the past have 
suggested that postmenopausal hormone therapy was associated with a reduction in risk of 
coronary heart disease by 40 to 50 percent46,47.  However, recent evidence from clinical trials 
have provided no evidence of cardiac protection and even some deleterious effects of hormone 
therapy use48-50.  Studies looking at the association between hormone therapy use and either 
arterial stiffness or inflammation have also been inconsistent51-54.  These inconsistencies could be 
attributed to differences in clinical characteristics of the study populations, including age, years 
since menopause, and risk of coronary heart disease.  Future studies are needed to ascertain 
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whether or not certain regimens of hormone therapy use may be more beneficial than others in 
reducing inflammation and arterial stiffness and how this translates into reduction of 
cardiovascular risk. 
There is evidence that the perimenopausal stage may confer a greater cardiovascular risk 
than the postmenopausal stage18.  Due to the small sample size of perimenopausal women, our 
study was not able to test differences in risk factors between perimenopausal and 
postmenopausal women.  In the first analysis, we showed that the association between 
inflammation and central arterial stiffness was stronger in women who were later in their 
transition than women who were earlier in their transition.  However, we were forced to collapse 
the late perimenopausal with the postmenopausal women and the early perimenopausal with the 
premenopausal women.  Future studies should examine tripartite differences between 
premenopausal, perimenopausal, and postmenopausal women.  This would help to identify the 
exact stage of the menopausal transition that begins to modify the effect of CRP on arterial 
stiffness. 
A limitation with the first analysis relates to the methodology used to measure carotid-
femoral pulse wave velocity.  The distance portion of the equation for pulse wave velocity was 
calculated as the distance between the carotid and femoral recordings measured over the surface 
of the body.  Because the proximal and distal pulse waves travel in opposite directions, the 
distance measured over the surface of the body may have increased error in the measurement.  In 
order to circumvent this problem, some authors have suggested subtracting the distance between 
the sternal notch to the carotid location from the total carotid-femoral distance.  However, this 
method would require two measurements of distance which could conceivably increase the 
error55. 
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A limitation with the second analysis was the composition of the population.  As a result 
of not having a large enough cuff size to cover the upper arm of a number of women, we were 
forced to exclude a disproportionate number of black and overweight women from the analysis.  
Thus, women from this study represented a healthy cohort and the results were not generalizable 
to all middle-aged women transitioning through menopause.  Because the heavier women 
constitute a high risk group, the association between CRP and distensibility would likely have 
been even stronger if these women had been included.  We are currently attempting to obtain 
measurements of distensibility on these women by either creating a larger cuff size or conducting 
the measurement on the forearm rather than the upper arm.  We conducted a reproducibility 
study to compare the distensibility measured in the upper arm with the distensibility measured in 
the forearm.  A total of twelve women between the ages of 24 and 63 had distensibility measured 
on the upper arm and forearm.  The mean upper arm value for the twelve volunteers was 
significantly greater than the mean forearm value.  A plot of the data showed that the 
distensibility measured in the upper arm was greater than the distensibility measured in the 
forearm in ten of the twelve women.  This would suggest the possibility of applying a correction 
formula to equate measurements from the upper arm with the forearm.  However, larger 
reproducibility studies are needed on a more homogeneous sample of women to justify the use of 
a correction formula. 
5.4 LIMITATIONS/FUTURE RESEARCH—ANALYSIS 3 
The third analysis prospectively examined the association between CRP and PAD in a cohort of 
older adults who were considered well functioning at the baseline visit of the study.  In order to 
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be eligible for the study, participants were required to walk one quarter mile, climb 10 steps, and 
perform basic activities of daily living without difficulty and not have any life-threatening 
illness.  Therefore, this cohort may not have been representative of the general population of 
older adults.  The population in this study may reflect a survival bias such that many of the 
unhealthy participants had died prior to the follow-up visit.  In this analysis, the participants who 
were excluded (many of who had died at the follow-up visit) had a worse baseline cardiovascular 
profile than participants who were included.  Future studies are needed to examine the 
association between CRP and PAD in unselected higher risk older individuals. 
The inflammatory markers and most covariates tested in this analysis were measured at a 
single baseline visit and the outcome variable (ABI) was measured at the baseline visit and a 
three year follow-up visit.  Thus, we were not able to test how the change in certain 
inflammatory markers affected the incidence of PAD.  Because the inflammatory markers and 
majority of covariates were only measured at baseline, we only adjusted for baseline covariates 
in the analysis.  Thus, we could not accurately control for the change in cardiovascular profile 
between the two visits (approximately 3 years).  However, when excluding individuals who had 
developed a clinical cardiovascular event between the two visits, we found similar results.  
Future studies are needed to test whether or not the change in CRP is associated with incidence 
of PAD.  
Because of the already limited number of incident PAD cases, we chose not to exclude 
participants who presented symptoms of intermittent claudication.  There is at least some 
evidence that individuals with intermittent claudication experience a greater decline in ABI over 
time than individuals without symptoms56.  However, our study did not have a large enough 
number of individuals with intermittent claudication to separate asymptomatic from symptomatic 
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PAD.  Therefore, future studies are needed to test whether or not the association between CRP 
and incident PAD is different among asymptomatic and symptomatic individuals. 
This study examined the association between baseline CRP markers and three year 
incidence of PAD.  Among the participants who had a high level of CRP but no incidence of 
PAD, it would be important to identify how many developed PAD in the future.  Three years 
may not have provided long enough time for many of these participants to develop PAD.  Future 
studies should be aimed at examining the association between CRP and incidence of PAD at 
multiple time points. 
Previous studies testing the association between proinflammatory cytokines and PAD 
have been inconsistent.  Our study did not find an association between IL-6 and TNF-α with 
incidence of PAD.  One study found IL-6 to be a stronger predictor than CRP of decrease in ABI 
over time.  However, a large percentage (24%) of their population already had PAD at the 
baseline visit and these participants were not excluded from the follow-up analysis.  Thus, it 
could be hypothesized that IL-6 acts at a later stage of the atherosclerotic process and CRP is a 
more sensitive marker of early atherosclerotic events.  Future prospective studies are needed to 
further distinguish the effects of different inflammatory markers on different stages of the 
atherosclerotic process. 
5.5 SUMMARY 
In summary, this research found a strong positive association between CRP and subclinical 
atherosclerosis in two distinct populations at increased risk of cardiovascular disease.  CRP was 
strongly associated with increased central and systemic arterial stiffness in a cohort of women 
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transitioning through menopause.  Additionally, CRP was associated with increased incidence of 
PAD in a cohort of older adults.  The strength of this study was in its ability to test the 
association between systemic inflammation and subclinical atherosclerosis in large multi-ethnic 
population based cohorts.  This research has provided evidence that CRP may directly promote 
early vascular damage in various arterial beds.   
5.6 PUBLIC HEALTH SIGNIFICANCE 
Early vascular damage is thought to precede clinical cardiovascular events in high risk 
populations.  CRP appears to be directly involved in promoting vascular damage.  Several 
behavioral interventions including weight loss57,58, physical activity59, diet4, and smoking 
cessation60 have been linked to lower CRP levels.  Additionally, pharmacological interventions 
including statins and angiotensin converting enzyme (ACE) inhibitors have also been recognized 
as having anti-inflammatory effects4.  This dissertation has provided strong evidence that CRP 
may promote early vascular damage in individuals at high risk for developing cardiovascular 
disease.  This is important because a reduction in CRP may reverse or prevent early detrimental 
vascular changes.  Given the overwhelming evidence that levels of CRP can be reduced with 
behavioral and pharmacological treatment, future randomized clinical trials should determine 
whether this reduction translates into diminished cardiovascular risk.     
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APPENDIX A 
DETAILED LITERATURE REVIEW OF STUDIES EXAMINING THE ASSOCIATION 
BETWEEN C-REACTIVE PROTEIN AND ARTERIAL STIFFNESS 
A.1 HEALTHY POPULATIONS 
Several studies have found an association between CRP and arterial stiffness in healthy 
populations.  One study examined the association between CRP and aortic pulse wave velocity in 
a cohort of 427 healthy subjects between the ages of 16 and 83 years1.  The gender distribution in 
the study was approximately equal (55% male, n=232). This study excluded subjects with 
diabetes, renal disease, and cardiovascular disease.  The authors examined CRP both as a 
categorical variable (using clinically defined cutpoints) and a log transformed continuous 
variable.  The mean CRP was 4.0 mg/L and 35.3% of the participants had a CRP greater than 3.0 
mg/L, a level that is considered high risk for future cardiovascular disease.  The primary finding 
was that mean aortic pulse wave velocity increased with increasing CRP risk groups (7.0 m/s for 
low risk CRP group, 7.6 m/s for moderate risk CRP group, 8.2 m/s for high risk CRP group, P-
value for trend=0.001).  After adjustment for age, mean arterial pressure, and gender, log 
transformed CRP was linearly associated with aortic pulse wave velocity (β=0.127, P=0.004).  A 
major limitation with this study was that the authors did not stratify by age.  Given the broad age 
range, it would be of interesting to know the contribution of age as an effect modifier.  Given the 
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inclusion of healthy subjects, the CRP levels in this study were surprisingly high.  This may be 
due to the fact that authors included participants with acute inflammation (CRP greater than 
10.0).  Clinically defined cutpoints for CRP are considered to be outdated because they are not 
representative of most populations.  The authors did repeat the analyses using tertiles but did not 
present the results. 
A community based study examined the association between CRP and arterial stiffness in 
214 asymptomatic Caucasian men and women2.  The mean age of the study was 59.6 ± 10.2 
years and the median CRP was 2.0.  Participants with a history of bypass surgery, angioplasty, 
coronary surgery, myocardial infarction, or stroke were excluded from the study.  After 
adjustment for age, heart rate, mean arterial pressure, BMI, and total and HDL cholesterol, log 
transformed CRP was associated with aortic pulse wave velocity (β=0.74, P<0.001).  Similar to 
the previous study, a major limitation is that the current study did not exclude participants with 
acute inflammation.  Although the subjects were considered asymptomatic, a large percentage 
(44%) was taking antihypertensive medications.  However, the authors made no mention of 
adjusting for medication use in the models. 
Two population based studies in healthy Japanese older adults tested the association 
between CRP and brachial ankle pulse wave velocity3,4.  The first study recruited 870 males and 
females between the ages of 40 and 79 years3.  The authors excluded subjects with heart disease 
or an ABI less than 0.9, women on hormone therapy, and individuals taking statins.  The mean 
age of the population was 59 years, the mean CRP was 0.82 mg/L, and approximately half of the 
population was male.  After adjustment for confounders, CRP was associated with log 
transformed pulse wave velocity (β=0.049, P<0.01).  The mean levels of CRP increased with 
increasing quartiles of pulse wave velocity (p for trend < 0.01).  A limitation of this study was 
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that the authors used the brachial ankle pulse wave velocity to represent aortic stiffness.  
Although it has been found to be correlated with aortic pulse wave velocity, studies are needed to 
test whether or not it can be used as a surrogate measure.  The second study examined the 
association between CRP and brachial ankle pulse wave velocity in a cohort of 2,678 Japanese 
men between the ages of 30 and 74 years4.  The mean age and CRP of the population was 43 
years and 1.2 mg/L respectively.  After adjustment for age, BMI, pulse pressure, and systolic 
blood pressure, log transformed CRP was not found to be associated with pulse wave velocity.  
Participants in the top quartile of pulse wave velocity had a significantly higher unadjusted mean 
CRP than subjects in the other three quartiles (p < 0.01).  The lack of association between 
continuous CRP and pulse wave velocity could have resulted from overadjusment due to 
inclusion of both pulse pressure and systolic blood pressure in the multivariate models.  The 
authors’ recruitment of a “healthy” population was questionable as they made no mention of 
excluding participants with clinical cardiovascular disease.  Additionally, they elicited confusion 
by mentioning the exclusion of women on hormone therapy. 
A.2 OLDER ADULT POPULATION 
The Rotterdam Study was the only population based study to examine the association between 
CRP and arterial stiffness in older adults who were not screened for cardiovascular disease5.  The 
population consisted of 866 men and women over the age of 55 years.  The mean age was 70.9 ± 
5.4 years and approximately half of the population was male.  After adjustment for age and 
gender, CRP was associated with increased carotid-femoral pulse wave velocity (β=0.138, 95% 
CI = 0.063 to 0.213).  After adjustment for additional confounders, the association was 
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attenuated but still significant.  When analyzing CRP as tertiles, the authors found an increase in 
adjusted mean pulse wave velocity with increasing tertiles of CRP.  One limitation of the study 
was that the authors chose to exclude logarithmic CRP values which were considered outliers.  
The transformation of data is used to normalize the distribution (and thus reduce outliers) and 
outliers should have been eliminated from the original untransformed data.  Another limitation is 
that the authors did not actually use the log transformed CRP in the multivariate regression 
models.  This could have resulted in violations of linear regression assumptions including 
linearity and normality. 
A.3 PATIENT STUDIES 
Several studies have investigated the association between CRP and arterial stiffness in patients 
with a systemic inflammatory disease.  One study recruited 53 patients over the age of 18 with 
rheumatoid arthritis (15 of which had coronary artery disease) and 53 age and sex matched 
controls without rheumatoid arthritis (15 of which had coronary artery disease) from two public 
and private clinics in Australia6.  Arterial stiffness was assessed by small and large artery 
elasticity, both of which are inversely related to pulse wave velocity.  The mean age of the 
patients and controls was 55 and 54 years respectively.  CRP was significantly greater in patients 
than controls (10.0 mg/L vs. 1.6 mg/L, p<0.001).  In the combined group of patients and 
controls, CRP was significantly inversely associated with both small and large artery elasticity 
after adjustment for age and sex (p<0.001 and p=.035 respectively).  However, when the groups 
were considered separately, no association was found.  It could be hypothesized that the study 
did not have enough power to test the association in patients.  However, an increase in sample 
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size may not have mattered because patients with rheumatoid arthritis in this study already had 
significant vascular damage.  Thus, levels of CRP in this subgroup may not have been associated 
with further damage to the arteries.  The authors in this study did not mention the techniques 
used to measure small and large artery elasticity.  Therefore, comparisons in the association 
between CRP and arterial stiffness according to artery size were not clear. 
Another study looked at the association between CRP and aortic pulse wave velocity in 
60 untreated hypercholesterolaemic patients and 25 age and sex matched controls7.  The 
investigators excluded participants with clinical cardiovascular disease, hypertension, or 
evidence of increased inflammation.  Additionally, smokers and participants taking anti-
inflammatory medications were excluded.  The mean age of the population was 57 years in both 
cases and controls and CRP was significantly higher in cases than controls (1.65 mg/L vs 0.7 
mg/L, p=0.03).  After adjustment for confounders, log transformed CRP was associated with 
increased pulse wave velocity in hypercholesterolaemic patients (β=0.30, p=0.03) and the 
combined sample (β=0.32, p=0.008).  Participants with a CRP greater than 3.0 mg/L had a 
higher age adjusted mean pulse wave velocity than the rest of the population.  One major 
limitation with this study was that the authors did not test whether the association between CRP 
and arterial stiffness was different in patients and controls.  Another limitation was reflected in 
the strict exclusion criteria.  The authors excluded patients with any history of hypertension, 
cardiovascular disease, or inflammation.  Additionally, smokers and participants taking 
antiplatelet, anti-inflammatory, or hypolipidemic agents were excluded.  Therefore, this 
population may have represented a healthy subgroup of patients with hypercholesterolaemia. 
Investigators from a specialized vasculitis clinic studied the association between CRP and 
aortic pulse wave velocity in a cohort of patients with small vessel vasculitis (n=31) and controls 
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(n=32) matched on age, sex, height, blood pressure, and cholesterol8.  The patients were 
separated into two groups—those with active disease (n=15) and those in remission (n=16).  The 
population ranged in age from 18 to 85 years with a mean of 55 years.  The unadjusted mean 
CRP was significantly higher in the active disease group (16.0 mg/L) compared to the remission 
(2.9 mg/L) and control groups (1.1 mg/L).  There was no significant difference in CRP between 
the remission and control groups.  After adjustment for confounders, log transformed CRP was 
significantly associated with increased pulse wave velocity (p=0.01).  As with the previous 
patient studies, small sample size was a major limitation.  Although the authors recruited cases 
and controls, they did not have the power to test whether or not the association between CRP and 
pulse wave velocity was different between the groups.  The finding that CRP levels were much 
lower in the remission group compared to the active disease group provides evidence that 
inflammation can be reduced with treatment. 
One study recruited 42 patients (83% male, n=35) with untreated hypertension and 42 age 
and sex matched controls9.  Individuals with diabetes, coronary artery disease, heart failure, 
hypercholesterolaemia, renal disease, acute inflammation (characterized by a CRP greater than 
5.0 mg/L), or anemia were excluded.  All participants were nonsmokers and none were taking 
vasocative or anti-inflammatory medications.  The authors used the travel time of the pulse wave 
to the periphery as a surrogate marker of aortic stiffness that is inversely related to the pulse 
wave velocity.  The mean age of the population was 52 years.  CRP was found to be significantly 
higher in the hypertensive group than the controls (1.27 mg/L vs 0.74 mg/L, p<.001).  After 
adjustment for confounders, the authors did not find a significant association between log 
transformed CRP and travel time of the pulse wave in either the controls or the hypertensive 
patients.  There were several notable limitations in this study.  Because of the stringent exclusion 
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criteria, the sample size in the study was small and may have affected the results.  A second 
limitation is that the study used an indirect measure of arterial stiffness that has not been well 
established as a surrogate marker.  Finally, the authors did not explain the apparent selection bias 
characterized by the disproportionate number of males. 
In summary, the current literature has provided compelling evidence of a strong 
relationship between CRP and arterial stiffness.  However, the role of ethnicity and the 
menopausal transition on this relationship has not been investigated.  This dissertation extends 
upon the literature by establishing a strong association between CRP and arterial stiffness in 
women transitioning through menopause.  Furthermore, this dissertation provides preliminary 
evidence that CRP is associated with systemic arterial stiffness.  Future longitudinal studies in 
ethnic diverse populations are needed to verify our findings. 
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APPENDIX B 
DETAILED LITERATURE REVIEW OF STUDIES EXAMINING THE ASSOCIATION 
BETWEEN C-REACTIVE PROTEIN AND PERIPHERAL ARTERIAL DISEASE 
B.1 CROSS-SECTIONAL STUDIES 
Several population based studies have looked at the association between CRP and peripheral 
arterial disease.  The InCHIANTI Study recruited 955 men and women over the age of 60 from 
two Italian communities10.  This study used an ABI less than 0.9 as an indicator of PAD.  
Participants with PAD were older (78.27 vs 73.78 years, p<0.001) and had higher levels of CRP 
(3.60 mg/dL vs 2.52 mg/dL, p=.001) than participants without PAD.  The association between 
CRP and PAD was attenuated but remained significant after adjustment for age, sex, BMI, 
smoking, comorbidities, and cholesterol.  Additional adjustment for physical activity further 
attenuated the association and results were no longer significant.  Although physical activity 
attenuated the association, the magnitude of the effect was extremely small.  The lack of 
significance may have simply been a result of a reduced sample size.  It would have been useful 
to know how many individuals were missing a physical activity score. 
Another study tested the association between CRP and PAD in 30 diabetic patients with 
PAD (defined by an ABI < 0.9) and 60 age and BMI matched controls (defined by an ABI 
between 1.0 and 1.3)11.  The authors excluded individuals with acute or chronic infectious 
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diseases, creatinine > 2.0 mg/dl, or chronic inflammatory diseases.  The mean age of the 
population was 67 years and the male to female ratio was approximately two to one.  The 
unadjusted median CRP was significantly greater in diabetic patients with PAD compared to 
diabetic patients without PAD (0.282 mg/dl vs 0.102 mg/dl, p<0.001).  Participants in the top 
tertile of CRP had a significant greater odds of having PAD than participants in the bottom tertile 
of CRP (OR=2.93, p=0.028).  A major limitation of this study is that the authors did not clearly 
define how and which confounders were adjusted for.  From the multivariate model, it is unclear 
whether they adjusted for age and smoking status.  Another limitation is that the authors made no 
mention of why individuals with an ABI between 0.9 and 1.0 were excluded from the analyses. 
A study of 370 men and women over the age of 55 with PAD (ABI < 0.9) and 321 
without PAD (ABI between 0.9 and 1.5) assessed the relationship between CRP and PAD12.  
Among participants without a history of cardiac or cerebrovascular disease, median levels of 
CRP were higher in PAD patients compared to controls (0.30 mg/dl vs 0.20 mg/dl, p < 0.01).  
However, CRP was not associated with PAD in patients with a history of cardiovascular or 
cerebrovascular disease.  After adjustment for confounders, log transformed CRP was only 
associated with decreasing ABI in patients without a history of cardiovascular or cerebrovascular 
disease (β= -0.034, p=0.026).  The major limitation of this study was that the authors did not 
perform the multivariate analysis with ABI as a dichotomous variable.  The authors 
simultaneously adjusted for several hemostatic factors but did not examine an additive effect.  
Furthermore, the inclusion of several hemostatic markers in a single model may have raised 
questions of colinearity. 
One study investigated the association between CRP and PAD in 89 healthy individuals 
without cardiovascular disease, diabetes, cancer, or kidney disease13.  The mean age of this 
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population was 51 years and approximately 85% was male.  The median CRP was higher in the 
patients with PAD compared to controls (4.95 vs 0.9, p < 0.001).  Among patients with PAD, the 
mean CRP increased with increasing severity of PAD.  One of the major limitations in this study 
is an obvious selection bias.  The authors gave no explanation for the disproportionate number of 
men in the study.  Another limitation is that the authors only presented the unadjusted results.  
Finally, the authors classified the study as prospective cohort but provided no information on the 
duration of the study. 
Another study examined the cross-sectional association between CRP and PAD along 
with the additive effect of CRP and PAD on clinical cardiovascular outcomes14.  This study 
recruited 110 men and women over the age of 18 years and followed them up for myocardial 
infarction, stroke, revascularization, or death.  At baseline, median levels of CRP were greater in 
patients with PAD compared to those without PAD (3.83 vs 2.11, p=0.019).  There appeared to 
be an additive effect of CRP and PAD on risk of outcome such that participants with high CRP 
and PAD had the highest risk of incurring an event.  One limitation of this study was that the 
authors did not give the follow-up time for the participants.  They provided the mean follow-up 
time but it would have been relevant to also provide the maximum follow-up time.  Additionally, 
it may have been more suitable to show a survival curve rather than an odds ratio.  Another 
limitation is that the authors only presented the unadjusted results for the association between 
CRP and PAD. 
The NHANES Study assessed the relationship between CRP and PAD among 4,787 men 
and women over the age of 40 years15.  To explore associations across range of ABI levels, the 
authors categorized ABI into 4 levels:  less than 0.9 (patients with PAD) and tertiles of ABI 
among participants without PAD (ABI greater than 0.9).  The mean CRP was found to decrease 
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across increasing categories of ABI (p for trend <0.001).  The age standardized prevalence of 
PAD increased with increasing quartiles of CRP (p < 0.01).  After adjustment for confounders, 
participants in the top quartile had a higher odds of prevalent PAD than those in the bottom 
quartile (OR=2.14, p<0.001).  The association between CRP and PAD was much stronger in 
Non-Hispanic blacks compared to Non-Hispanic whites (OR=3.10 vs 1.50, p for interaction = 
0.049) and younger adults compared to older adults (OR=5.59 vs 0.98, p for interaction = 0.018).  
The strongest finding of this study was the notable subgroup differences in the association 
between CRP and PAD.  Contrary to our study, this study showed a stronger association among 
blacks compared to whites.  This could be related to the younger and healthier population that 
these authors studied.  In addition to the authors’ categorization of ABI, it may have been 
interesting to categorize ABI according to severity of PAD.  However, sample size restrictions 
may have limited their ability to do this. 
B.2 PROSPECTIVE STUDIES 
The Physicians’ Health Study examined the association between CRP and future risk of 
developing PAD among 288 healthy men16.  Cases of PAD were defined as individuals who self-
reported symptoms of intermittent claudication or had revascularization procedures.  Controls 
were randomly selected participants matched on age, smoking habit, and length of follow-up.  
The mean age of the population was 63 years.  Participants in the highest quartile of CRP had 
twice the risk of developing PAD compared to those in the lowest quartile.  One limitation is that 
the authors used prospective data but selected cases and controls a priori.  Another limitation is 
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that they only looked at symptomatic cases of PAD, which would severely underestimate the true 
incidence of PAD. 
The Edinburgh Artery Study is the only other study that has looked at the prospective 
association between CRP and subclinical PAD, assessed by the ABI17.  This study examined 
CRP at baseline in 1,582 men and women between the ages of 55 and 74 years.  Additionally, 
they measured ABI at baseline, a 5 year, and 12 year follow-up visit.  The authors used 
progression of ABI, defined as change in ABI from baseline to each follow-up visit, as their 
primary outcome variable.  The mean age of the population at baseline was 64.8 years and 
approximately half (50.9%) of the population was male.  At baseline, mean CRP was higher in 
individuals with symptomatic PAD (intermittent claudication as assessed by WHO) compared to 
individuals with asymptomatic PAD (ABI < 0.9 but no symptoms of intermittent claudication) or 
controls.  After adjustment for risk factors, baseline levels of CRP were associated with 
decreasing 12 year decline in ABI (β= -0.018, p < 0.01) but not 5 year decline in ABI.  The 
primary limitation of this study is that the authors used ABI as a continuous measure but did not 
exclude individuals with PAD at baseline.  Thus, their conclusions related to progression rather 
than incidence of PAD.  It might have been interesting for the authors to stratify the analysis 
according to baseline levels of ABI and compare the differential association between CRP and 
PAD. 
In summary, several studies have examined the association between CRP and PAD both 
cross-sectionally and prospectively.  The prospective studies were either restricted to 
symptomatic cases of PAD or focused on progression of PAD.  Our study adds to the literature  
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by focusing on the relationship between CRP and incidence of PAD in both asymptomatic and 
symptomatic individuals.  Furthermore, our study was able to examine ethnic differences in this 
association. 
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